[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_byId_e3573e63-2c9c-47a7-85c3-ccaf9e99ce84":3,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:e3573e63-2c9c-47a7-85c3-ccaf9e99ce84,\"}":98},{"code":4,"data":5,"meta":18},"SUCCESS",{"id":6,"createTime":7,"updateTime":8,"relativeEntities":9,"slug":10,"properties":11,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":20,"manageAffiliations":45,"indexDatabases":57,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},"e3573e63-2c9c-47a7-85c3-ccaf9e99ce84","2023-12-05T05:55:44.205+00:00","2025-11-21T09:53:58.493+00:00",[],"European-Journal-of-Pharmaceutics-and-Biopharmaceutics",{"issn":12,"title":14},{"VOID":13},"09396411",{"EN":15},"European Journal of Pharmaceutics and Biopharmaceutics","PUBLISHER","PENDING",null,0,[21,29,37],{"id":22,"createTime":23,"updateTime":24,"relativeEntities":25,"label":26,"description":28,"parentId":18,"standard":18,"scholarHubFieldId":18},"988aad6e-c496-4836-b969-f61991a0eed2","2023-05-29T10:24:08.494+00:00","2023-11-21T05:14:42.646+00:00",[],{"EN":27},"Pharmaceutical Science",{},{"id":30,"createTime":31,"updateTime":32,"relativeEntities":33,"label":34,"description":36,"parentId":18,"standard":18,"scholarHubFieldId":18},"0254e3e5-c28d-4a33-83da-81bc94d29ffd","2023-05-29T10:24:00.931+00:00","2023-11-21T07:56:41.438+00:00",[],{"EN":35},"Medicine (miscellaneous)",{},{"id":38,"createTime":39,"updateTime":40,"relativeEntities":41,"label":42,"description":44,"parentId":18,"standard":18,"scholarHubFieldId":18},"d41d212f-54a7-479d-b0df-a39412128545","2023-05-29T10:24:01.414+00:00","2023-11-21T07:56:41.421+00:00",[],{"EN":43},"Biotechnology",{},[46],{"id":47,"createTime":48,"updateTime":49,"relativeEntities":50,"slug":51,"properties":52,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":55,"url":18,"parentIds":56,"statistic":18},"c749757b-dddf-4e6f-9697-b9c441adc06c","2023-05-29T10:24:07.401+00:00","2025-11-21T10:06:14.206+00:00",[],"Elsevier",{"title":53},{"EN":51},"AFFILIATION",11,[],[58,77],{"id":59,"indexDatabase":60,"url":74,"indexYears":18,"academicFieldIds":75,"indexDatabaseRanking":18},"c94799de-b9d4-4b78-a8de-6b8ffe0398e1",{"id":61,"createTime":62,"updateTime":63,"relativeEntities":64,"label":65,"description":67,"key":70,"publicationTags":71,"standard":18},"a4921856-b128-4d9f-8f1f-e80813d3bbd4","2023-05-22T09:59:31.026+00:00","2025-11-21T10:07:52.153+00:00",[],{"EN":66,"VI":66},"ISI\u002FSCIE - Science Citation Index Expanded",{"VI":68,"EN":69},"Cơ sở dữ liệu SCIE","SCIE database","scie",[72,73],"SCIE","ISI","https:\u002F\u002Fmjl.clarivate.com\u002Fsearch-results?issn=0939-6411",[76],"2b943d65-24a8-4546-9232-a1e32c12cb6c",{"id":78,"indexDatabase":79,"url":91,"indexYears":92,"academicFieldIds":93,"indexDatabaseRanking":97},"ac6fe92c-0ddc-4344-85a0-f2671163ef49",{"id":80,"createTime":81,"updateTime":82,"relativeEntities":83,"label":84,"description":86,"key":88,"publicationTags":89,"standard":18},"3c7051d4-eb7d-4c57-a56b-36fc74c5d1e9","2023-05-22T09:57:18.509+00:00","2025-11-21T10:07:52.274+00:00",[],{"EN":85,"VI":85},"Scopus - Elsevier",{"EN":85,"VI":87},"Cơ sở dữ liệu Scopus thuộc Elsevier","scopus",[90],"SCOPUS","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002F21332","1991-2025",[94,95,96],"6fecd02d-a81f-4676-aae7-14033a2470d7","6e740848-171b-4f21-8d03-9fed10ed0384","e89cebf4-fecf-4b74-8ab4-88fca891e4c2","SCOPUS__Q1",{"meta":99,"data":101},{"total":100},"2620",[102,285,442,572,674,833,972,1033,1116,1215],{"id":103,"createTime":104,"updateTime":105,"relativeEntities":106,"slug":107,"properties":108,"entityType":115,"verifyStatus":116,"verifyTime":105,"verifyNote":117,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":118,"fullTextUrl":18,"authors":119,"publicationType":253,"publisherRelationship":254,"citationCount":18,"citationInfo":18,"publishDate":282,"publishYear":283,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":284},"c15b2fd7-f47a-44dd-9b71-0c6d3dd0dc50","2024-01-28T08:40:13.016+00:00","2025-01-14T23:57:36.874+00:00",[],"Co-amorphous-formulation-of-dipyridamole-with-p-hydroxybenzoic-acid-Underlying-molecular-mechanisms-physical-stability-dissolution-behavior-and-pharmacokinetic-study",{"references":109,"title":111,"doi":113},{"VOID":110},"Parmar, 2021, Pharmaceutical nanocrystals: a promising approach for improved topical drug delivery, Drug Discov. Today, 27, 1236\nWenlock, 2013, In silico physicochemical parameter predictions, Mol. Pharm., 10, 1224, 10.1021\u002Fmp300537k\nZarmpi, 2020, Biopharmaceutical understanding of excipient variability on drug apparent solubility based on drug physicochemical properties: case study—hypromellose (HPMC), AAPS J., 22, 1\nXu, 2021, An investigation on the effect of drug physicochemical properties on the enhancement strength of enhancer: the role of drug-skin-enhancer interactions, Int. J. Pharm., 607, 10.1016\u002Fj.ijpharm.2021.120945\nWilliams, 2013, Strategies to address low drug solubility in discovery and development, Pharmacol. Rev., 65, 315, 10.1124\u002Fpr.112.005660\nByrn, 2010, Accelerating proof of concept for small molecule drugs using solid-state chemistry, J. Pharm. Sci., 99, 3665, 10.1002\u002Fjps.22215\nMannully, 2019, Lipid modification of staphylokinase and its implications on stability and activity, Int. J. Boil. Macromol., 121, 1037, 10.1016\u002Fj.ijbiomac.2018.10.134\nDi, 2009, Drug-like property concepts in pharmaceutical design, Curr. Pharm. Des., 15, 2184, 10.2174\u002F138161209788682479\nAmidon, 1995, A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm. Res., 12, 413, 10.1023\u002FA:1016212804288\nMaghsoodi, 2020, Rational selection of formulation components to improve dissolution of dipyridamole, J. Drug Deliv. Sci. Technol., 55\nStocker, 2020, Spray encapsulation as a formulation strategy for drug-based room temperature ionic liquids: exploiting drug-polymer immiscibility to enable processing for solid dosage forms, Mol. Pharm., 17, 3412, 10.1021\u002Facs.molpharmaceut.0c00467\nZhang, 2015, From a binary salt to salt co-crystals of antibacterial agent lomefloxacin with improved solubility and bioavailability, Acta Crystallogr. B, 71, 437, 10.1107\u002FS2052520615011191\nSkieneh, 2017, Co-amorphous form of curcumin–folic acid dihydrate with increased dissolution rate, Cryst. Growth Des., 17, 6273, 10.1021\u002Facs.cgd.7b00947\nKhadka, 2021, Pharmacokinetics of rifampicin after repeated intra-tracheal administration of amorphous and crystalline powder formulations to Sprague Dawley rats, Eur. J. Pharm. Biopharm., 162, 1, 10.1016\u002Fj.ejpb.2021.02.011\nEmer, 2021, Design and characterisation of an amorphous formulation of nifedipine for the treatment of autonomic dysreflexia, J. Phar. Pharmacol., 73, 928, 10.1093\u002Fjpp\u002Frgab034\nSapkal, 2018, Solid dispersion of valsartan for solubility improvement using betacyclodextrin, MOJ Bioequiv. Availab., 5, 313\nMedarević, 2018, Assessing the potential of solid dispersions to improve dissolution rate and bioavailability of valsartan: in vitro-in silico approach, Eur. J. Pharm. Sci., 124, 188, 10.1016\u002Fj.ejps.2018.08.026\nUeda, 2019, Molecular mobility suppression of ibuprofen-rich amorphous nanodroplets by HPMC revealed by NMR relaxometry and its significance with respect to crystallization inhibition, Mol. Pharmaceutics, 16, 4968, 10.1021\u002Facs.molpharmaceut.9b00840\nHoppu, 2009, Rheology and molecular mobility of amorphous blends of citric acid and paracetamol, Eur. J. Pharm. Biopharm., 71, 55, 10.1016\u002Fj.ejpb.2008.06.029\nDengale, 2016, Recent advances in co-amorphous drug formulations, Adv. Drug Deliv. Rev., 100, 116, 10.1016\u002Fj.addr.2015.12.009\nWang, 2022, Platensimycin-berberine chloride co-amorphous drug system: Sustained release and prolonged half-life, Eur. J. Pharm. Biopharm., 179, 126, 10.1016\u002Fj.ejpb.2022.09.002\nKim, 2008, Translational therapeutics of dipyridamole, Arterioscler. Thromb. Vasc. Biol., 28, s39, 10.1161\u002FATVBAHA.107.160226\nEl-Sisi, 2020, Enhanced anticancer activity of combined treatment of imatinib and dipyridamole in solid ehrlich carcinoma-bearing mice, Naunyn Schmiedebergs Arch. Pharmacol., 383, 1113, 10.1007\u002Fs00210-019-01803-2\nThomé, 2019, Dipyridamole impairs autophagic flux and exerts antiproliferative activity on prostate cancer cells, Exp. Cell Res., 382, 10.1016\u002Fj.yexcr.2019.06.001\nGuo, 2010, Amelioration of inflammation and cytotoxicity by dipyridamole in brain endothelial cells, Cerebrovasc. Dis., 30, 290, 10.1159\u002F000319072\nTerhaag, 1986, The absolute and relative bioavailability of dipyridamole from different preparations and the in vitro-in vivo comparison, Int. J. Clin. Pharmacol. Ther. Toxicol., 24, 298\nRussell, 1994, pH-related changes in the absorption of dipyridamole in the elderly, Pharm. Res., 11, 136, 10.1023\u002FA:1018918316253\nVepuri, 2016, Synthesis, characterization and molecular modelling of a novel dipyridamole supramolecule – X-ray structure, quantum mechanics and molecular dynamics study to comprehend the hydrogen bond structure-activity relationship, J. Mol. Struct., 1105, 194, 10.1016\u002Fj.molstruc.2015.10.050\nBaghel, 2018, An investigation into the solid-state properties and dissolution profile of spray dried ternary amorphous solid dispersions: a rational step towards the design and development of multi-component amorphous system, Mol. Pharm., 15, 3796, 10.1021\u002Facs.molpharmaceut.8b00306\nSanganwar, 2009, Nano-mixing of dipyridamole drug and excipient nanoparticles by sonication in liquid CO2, Powder Technol., 196, 36, 10.1016\u002Fj.powtec.2009.06.015\nXi, 2019, Development and evaluation of dipyridamole sustained release tablets containing micro-environmental pH modifiers, J. Drug Deliv. Sci. Technol., 54\nRicevuti, 1991, Pharmacokinetics of dipyridamole-beta-cyclodextrin complex in healthy volunteers after single and multiple doses, Eur. J. Drug Metab. Pharmacokinet., 16, 197, 10.1007\u002FBF03189959\nKostenbauder, 2010, Formation of molecular complexes by some water-soluble amides interaction of several amides with p-hydroxybenzoic acid, salicylic acid, chloramphenicol, and phenol, J. Phar. Sci., 45, 518, 10.1002\u002Fjps.3030450804\nSun, 2022, Evaluation of kinetic stability of dipyridamole amorphous drug system, J. Shihezi U. (Natural Science), 40, 21\nM.J. Frisch, G.W. Trucks, H.B. Schlegel, G.E. Scuseria, M.A. Robb, J.R. Cheeseman, G. Scalmani, V. Barone, G.A. Petersson, H. Nakatsuji, X. Li, M. Caricato, A. Marenich, J. Bloino, B.G. Janesko, R. Gomperts, B. Mennucci, H.P. Hratchian, J.V. Ortiz, A.F. Izmaylov, J.L. Sonnenberg, D. Williams-Young, F. Ding, F. Lipparini, F. Egidi, J. Goings, B. Peng, A. Petrone, T. Henderson, D. Ranasinghe, V.G. Zakrzewski, J. Gao, N. Rega, G. Zheng, W. LiangM. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, K. Throssell, J.J.A. Montgomery, J.E. Peralta, F. Ogliaro, M. Bearpark, J.J. Heyd, E. Brothers, K.N. Kudin, V.N. Staroverov, T. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J.C. Burant, S.S. Iyengar, J. Tomasi, M. Cossi, J.M.illam, M. Klene, C. Adamo, R. Cammi, J.W. Ochterski, R.L. Martin, K. Morokuma, O. Farkas, J.B. Foresman, D.J. Fox, Gaussian 09, Revision A. 02 (2016) Gaussian, Inc.: Wallingford CT.\nDedroog, 2019, Solid-state analysis of amorphous solid dispersions: why DSC and XRPD may not be regarded as stand-alone techniques, J. Pharm. Biomed. Anal., 178\nBerbenni, 2002, Thermoanalytical and spectroscopic characterization of solid state dipyridamole, J. Therm. Anal. Calorim., 68, 413, 10.1023\u002FA:1016075332451\nKumar, 2017, Pharmaceutical cocrystals: an overview, Indian J. Pharm. Sci., 79, 858, 10.4172\u002Fpharmaceutical-sciences.1000302\nShi, 2020, Ibrutinib and carboxylic acid co-amorphous system with increased solubility and dissolution: a potential interaction mechanism, J. Drug Deliv. Sci. Tec., 59\nCruz-Cabeza, 2012, Acid–base crystalline complexes and the pKa rule, CrystEngComm., 14, 6362, 10.1039\u002Fc2ce26055g\nLiu, 2020, Determination of the optimal molar ratio in amino acid-based co-amorphous systems, Mol. Pharm., 17, 1335, 10.1021\u002Facs.molpharmaceut.0c00042\nUeda, 2018, Application of a salt coformer in a co-Amorphous drug system dramatically enhances the glass transition temperature: a case study of the ternary system carbamazepine, citric acid, and L-arginine, Mol. Pharm., 15, 2036, 10.1021\u002Facs.molpharmaceut.8b00174\nFox, 1956, Influence of diluent and of copolymer composition on the glass temperature of a polymer system, Bull. Am. Phys. Soc., 1, 123\nSakka, 1971, Relation between apparent glass transition temperature and liquids temperature for inorganic glasses, J. Non Cryst. Solids, 6, 145, 10.1016\u002F0022-3093(71)90053-6\nBraun, 2012, Complex polymorphic system of gallic acid−five monohydrates, three anhydrates, and over 20 solvates, Cryst. Growth Des., 13, 19, 10.1021\u002Fcg301506x\nHeinz, 2009, Analysis of solid-state transformations of pharmaceutical compounds using vibrational spectroscopy, J. Pharm. Pharmacol., 61, 971, 10.1211\u002Fjpp.61.08.0001\nTaylor, 2000, Evaluation of solid-state forms present in tablets by Raman spectroscopy, J. Pharm. Sci., 89, 1342, 10.1002\u002F1520-6017(200010)89:10\u003C1342::AID-JPS12>3.0.CO;2-X\nAndrews, 2010, Physicochemical characterization and drug-release properties of celecoxib hot-melt extruded glass solutions, J. Pharm. Pharmacol., 62, 1580, 10.1111\u002Fj.2042-7158.2010.01177.x\nLafi, 2012, Glass transition kinetics and crystallization mechanism in Se90Cd8Bi2 and Se90Cd6Bi4 chalcogenide glasses, J. Alloys. Compd., 519, 123, 10.1016\u002Fj.jallcom.2011.12.125\nImran, 2011, Crystallization kinetics, glass transition kinetics, and thermal stability of Se70-xGa30Inx (x=5, 10, 15, and 20) semiconducting glasses, Physica B Condens. Matter, 406, 482, 10.1016\u002Fj.physb.2010.11.019\nNehm, 2006, Phase solubility diagrams of cocrystals are explained by solubility product and solution complexation, Cryst. Growth Des., 6, 592, 10.1021\u002Fcg0503346\nRen, 2021, Gelation of small molecule amorphous drugs, Acta Pharm. Sin., 56, 855\nAbbiati, 2017, Enterohepatic circulation effect in physiologically based pharmacokinetic models: the sorafenib case, Ind. Eng. Chem. Res., 56, 3156, 10.1021\u002Facs.iecr.6b03686\nTerhaag, 1986, The absolute and relative bioavailability of dipyridamole from different preparations and the in vitro-in vivo comparison, Int. J. Clin. Pharmacol. Ther., 24, 298",{"EN":112},"Co-amorphous formulation of dipyridamole with p-hydroxybenzoic acid: Underlying molecular mechanisms, physical stability, dissolution behavior and pharmacokinetic study",{"VOID":114},"10.1016\u002Fj.ejpb.2023.01.018","PUBLICATION","VERIFIED","Auto Verify","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0939641123000188",[120,137,150,163,176,189,202,214,227,240],{"id":121,"sortIndex":122,"researcher":18,"roles":123,"affiliations":125,"properties":134},"dcc86d27-93b1-453b-9cc4-9ce3113f19f1",4,[124],"AUTHOR",[126],{"id":18,"sortIndex":19,"affiliation":127,"properties":18},{"id":128,"createTime":129,"updateTime":129,"relativeEntities":130,"slug":18,"properties":131,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"791e6f74-b6c2-46fb-ba51-d404b77fa068","2024-01-01T06:30:38.750+00:00",[],{"title":132},{"VI":133},"School of Pharmacy, Key Laboratory of Innovative Drug Development and Evaluation, Hebei Medical University, Shijiazhuang 050017, People’s Republic of China",{"title":135},{"VI":136},"Yawen Tian",{"id":138,"sortIndex":139,"researcher":18,"roles":140,"affiliations":141,"properties":147},"9bcf1a0a-8197-4c96-aba4-2e4f63d98077",5,[124],[142],{"id":18,"sortIndex":19,"affiliation":143,"properties":18},{"id":128,"createTime":129,"updateTime":129,"relativeEntities":144,"slug":18,"properties":145,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":146},{"VI":133},{"title":148},{"VI":149},"Huibing Gao",{"id":151,"sortIndex":152,"researcher":18,"roles":153,"affiliations":154,"properties":160},"fe50a84d-c157-47d5-bd5e-509032ac79b6",2,[124],[155],{"id":18,"sortIndex":19,"affiliation":156,"properties":18},{"id":128,"createTime":129,"updateTime":129,"relativeEntities":157,"slug":18,"properties":158,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":159},{"VI":133},{"title":161},{"VI":162},"Yuanchun Li",{"id":164,"sortIndex":165,"researcher":18,"roles":166,"affiliations":167,"properties":173},"f557a96b-0860-42ce-9e8b-9e8f476baa6f",3,[124],[168],{"id":18,"sortIndex":19,"affiliation":169,"properties":18},{"id":128,"createTime":129,"updateTime":129,"relativeEntities":170,"slug":18,"properties":171,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":172},{"VI":133},{"title":174},{"VI":175},"Congwei Li",{"id":177,"sortIndex":178,"researcher":18,"roles":179,"affiliations":180,"properties":186},"7b77a069-176d-4409-bdfd-d3832f69d04e",9,[124],[181],{"id":18,"sortIndex":19,"affiliation":182,"properties":18},{"id":128,"createTime":129,"updateTime":129,"relativeEntities":183,"slug":18,"properties":184,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":185},{"VI":133},{"title":187},{"VI":188},"Caiqin Yang",{"id":190,"sortIndex":191,"researcher":18,"roles":192,"affiliations":193,"properties":199},"7b48a182-2aa2-4a9f-905d-4d48ea800f1f",6,[124],[194],{"id":18,"sortIndex":19,"affiliation":195,"properties":18},{"id":128,"createTime":129,"updateTime":129,"relativeEntities":196,"slug":18,"properties":197,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":198},{"VI":133},{"title":200},{"VI":201},"Tiantian Li",{"id":203,"sortIndex":19,"researcher":18,"roles":204,"affiliations":205,"properties":211},"afcb7139-5678-4989-9921-dc5df20e9d16",[124],[206],{"id":18,"sortIndex":19,"affiliation":207,"properties":18},{"id":128,"createTime":129,"updateTime":129,"relativeEntities":208,"slug":18,"properties":209,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":210},{"VI":133},{"title":212},{"VI":213},"Wei Guo",{"id":215,"sortIndex":216,"researcher":18,"roles":217,"affiliations":218,"properties":224},"b626e6fd-c0cf-4710-8265-c8b787609eb8",7,[124],[219],{"id":18,"sortIndex":19,"affiliation":220,"properties":18},{"id":128,"createTime":129,"updateTime":129,"relativeEntities":221,"slug":18,"properties":222,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":223},{"VI":133},{"title":225},{"VI":226},"Hanruo Zhu",{"id":228,"sortIndex":229,"researcher":18,"roles":230,"affiliations":231,"properties":237},"057965d3-9405-451a-8abb-8cde13e6c2c8",8,[124],[232],{"id":18,"sortIndex":19,"affiliation":233,"properties":18},{"id":128,"createTime":129,"updateTime":129,"relativeEntities":234,"slug":18,"properties":235,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":236},{"VI":133},{"title":238},{"VI":239},"Jing Wang",{"id":241,"sortIndex":242,"researcher":18,"roles":243,"affiliations":244,"properties":250},"84ea5edf-1f8b-444f-909b-f1b675bd48ea",1,[124],[245],{"id":18,"sortIndex":19,"affiliation":246,"properties":18},{"id":128,"createTime":129,"updateTime":129,"relativeEntities":247,"slug":18,"properties":248,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":249},{"VI":133},{"title":251},{"VI":252},"Xueqing Dong","ARTICLE",{"url":118,"publisher":255,"properties":277},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":256,"slug":10,"properties":257,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":260,"manageAffiliations":261,"indexDatabases":262,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":258,"title":259},{"VOID":13},{"EN":15},[],[],[263,270],{"id":78,"indexDatabase":264,"url":91,"indexYears":92,"academicFieldIds":269,"indexDatabaseRanking":97},{"id":80,"createTime":81,"updateTime":82,"relativeEntities":265,"label":266,"description":267,"key":88,"publicationTags":268,"standard":18},[],{"EN":85,"VI":85},{"EN":85,"VI":87},[90],[94,95,96],{"id":59,"indexDatabase":271,"url":74,"indexYears":18,"academicFieldIds":276,"indexDatabaseRanking":18},{"id":61,"createTime":62,"updateTime":63,"relativeEntities":272,"label":273,"description":274,"key":70,"publicationTags":275,"standard":18},[],{"EN":66,"VI":66},{"VI":68,"EN":69},[72,73],[76],{"volume":278,"pages":280},{"VOID":279},"184",{"VOID":281},"139-149","2023-03-01",2023,false,{"id":286,"createTime":287,"updateTime":288,"relativeEntities":289,"slug":290,"properties":291,"entityType":115,"verifyStatus":116,"verifyTime":288,"verifyNote":117,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":298,"fullTextUrl":18,"authors":299,"publicationType":253,"publisherRelationship":412,"citationCount":18,"citationInfo":18,"publishDate":440,"publishYear":441,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":284},"ee24fd41-e2ec-4e96-87bb-fa91bdea3c7e","2024-01-12T18:13:42.849+00:00","2024-12-12T23:57:22.531+00:00",[],"Formulation-of-itraconazole-nanococrystals-and-evaluation-of-their-bioavailability-in-dogs",{"references":292,"title":294,"doi":296},{"VOID":293},"Merisko-Liversidge, 2011, Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology, Adv. Drug Deliv. Rev., 63, 427, 10.1016\u002Fj.addr.2010.12.007\nVan Eerdenbrugh, 2008, Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products, Int. J. Pharm., 364, 64, 10.1016\u002Fj.ijpharm.2008.07.023\nSingh, 2011, Oral formulation strategies to improve solubility of poorly water-soluble drugs, Expert Opin. Drug Deliv., 8, 1361, 10.1517\u002F17425247.2011.606808\nPeeters, 2002, Characterization of the Interaction of 2-hydroxypropyl-beta-cyclodextrin with itraconazole at pH 2, 4, and 7, J. Pharm. Sci., 91, 1414, 10.1002\u002Fjps.10126\nV. De Conde, P. Gilis, R. Vandercruys, Beads having a Core Coated with an Antifungal and a Polymer, U.S. Patent 5633015, 1997.\nSix, 2003, Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion, part II, Pharm. Res., 20, 1047, 10.1023\u002FA:1024414423779\nVerreck, 2003, Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion – part I, Int. J. Pharm., 251, 165, 10.1016\u002FS0378-5173(02)00591-4\nShiraki, 2008, Dissolution improvement and the mechanism of the improvement from cocrystallization of poorly water-soluble compounds, Pharm. Res., 25, 2581, 10.1007\u002Fs11095-008-9676-2\nRemenar, 2003, Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids, J. Am. Chem. Soc., 125, 8456, 10.1021\u002Fja035776p\nFDA, Guidance for Industry: Regulatory Classification of Pharmaceutical Cocrystals, in: F.a.D.A. US Department of Health and Human Services, Center for Drug Evaluation and Research (CDER) (Ed.), 2011.\nFriscic, 2010, Benefits of cocrystallisation in pharmaceutical materials science: an update, J. Pharm. Pharmacol., 62, 1547, 10.1111\u002Fj.2042-7158.2010.01133.x\nHickey, 2007, Performance comparison of a co-crystal of carbamazepine with marketed product, Eur. J. Pharm. Biopharm., 67, 112, 10.1016\u002Fj.ejpb.2006.12.016\nBasavoju, 2008, Indomethacin-saccharin cocrystal: design, synthesis and preliminary pharmaceutical characterization, Pharm. Res., 25, 530, 10.1007\u002Fs11095-007-9394-1\nTakata, 2010, A Spironolactone-Saccharin 1:1 Cocrystal Hemihydrate, Cryst. Growth Des., 10, 2116, 10.1021\u002Fcg901242q\nFriscic, 2009, The role of solvent in mechanochemical and sonochemical cocrystal formation: a solubility-based approach for predicting cocrystallisation outcome, CrystEngComm, 11, 418, 10.1039\u002FB815174A\nAher, 2010, Ultrasound assisted cocrystallization from solution (USSC) containing a non-congruently soluble cocrystal component pair: caffeine\u002Fmaleic acid, Eur. J. Pharm. Sci., 41, 597, 10.1016\u002Fj.ejps.2010.08.012\nDhumal, 2010, Cocrystalization and simultaneous agglomeration using hot melt extrusion, Pharm. Res., 27, 2725, 10.1007\u002Fs11095-010-0273-9\nSeefeldt, 2007, Crystallization pathways and kinetics of carbamazepine-nicotinamide cocrystals from the amorphous state by in situ thermomicroscopy, spectroscopy and calorimetry studies, J. Pharm. Sci., 96, 1147, 10.1002\u002Fjps.20945\nTrask, 2005, Pharmaceutical cocrystallization: engineering a remedy for caffeine hydration, Cryst. Growth Des., 5, 1013, 10.1021\u002Fcg0496540\nBysouth, 2011, Cocrystallization via planetary milling: enhancing throughput of solid-state screening methods, Int. J. Pharm., 411, 169, 10.1016\u002Fj.ijpharm.2011.03.037\nShan, 2002, Mechanochemistry and co-crystal formation: effect of solvent on reaction kinetics, Chem. Commun., 2372, 10.1039\u002Fb207369m\nWeyna, 2009, Synthesis and structural characterization of cocrystals and pharmaceutical cocrystals: mechanochemistry vs slow evaporation from solution, Cryst. Growth Des., 9, 1106, 10.1021\u002Fcg800936d\nVan Eerdenbrugh, 2008, Drying of crystalline drug nanosuspensions – the importance of surface hydrophobicity on dissolution behavior upon redispersion, Eur. J. Pharm. Sci., 35, 127, 10.1016\u002Fj.ejps.2008.06.009\nKumar, 2005, Hydrogen bonding and molecular vibrations of 3,5-diamino-1,2,4-triazole, Spectrochim. Acta Part A-Mol. Biomol. Spectrosc., 61, 261, 10.1016\u002Fj.saa.2004.03.039\nChaubal, 2008, Conversion of nanosuspensions into dry powders by spray drying: a case study, Pharm. Res., 25, 2302, 10.1007\u002Fs11095-008-9625-0\nLui, 1986, Comparison of gastrointestinal ph in dogs and humans – implications on the use of the beagle dog as a model for oral absorption in humans, J. Pharm. Sci., 75, 271, 10.1002\u002Fjps.2600750313",{"EN":295},"Formulation of itraconazole nanococrystals and evaluation of their bioavailability in dogs",{"VOID":297},"10.1016\u002Fj.ejpb.2013.12.016","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0939641113003986",[300,317,332,349,361,376,388,400],{"id":301,"sortIndex":242,"researcher":18,"roles":302,"affiliations":303,"properties":314},"ad97dcf5-406d-4f20-8598-eee4beed976b",[124],[304],{"id":18,"sortIndex":19,"affiliation":305,"properties":18},{"id":306,"createTime":307,"updateTime":308,"relativeEntities":309,"slug":310,"properties":311,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"a8e639b8-68de-4700-8a80-269018769f51","2023-12-07T11:33:05.330+00:00","2024-10-07T08:13:07.049+00:00",[],"Laboratory-of-Pharmaceutical-Process-Analytical-Technology-Ghent-University-Ghent-Belgium",{"title":312},{"VI":313},"Laboratory of Pharmaceutical Process Analytical Technology, Ghent University, Ghent, Belgium",{"title":315},{"VI":316},"Lien Saerens",{"id":318,"sortIndex":165,"researcher":18,"roles":319,"affiliations":320,"properties":329},"a53083af-67f1-4b96-9bf0-4780df08952f",[124],[321],{"id":18,"sortIndex":19,"affiliation":322,"properties":18},{"id":323,"createTime":324,"updateTime":324,"relativeEntities":325,"slug":18,"properties":326,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"e0c28bcb-1858-42a5-b82d-64e06b1e5c4e","2024-01-12T18:13:42.912+00:00",[],{"title":327},{"VI":328},"Applied and Analytical Chemistry, Hasselt University, Diepenbeek, Belgium",{"title":330},{"VI":331},"Robert Carleer",{"id":333,"sortIndex":19,"researcher":18,"roles":334,"affiliations":335,"properties":346},"0e9502af-6607-4976-9acc-da1e21130fb1",[124],[336],{"id":18,"sortIndex":19,"affiliation":337,"properties":18},{"id":338,"createTime":339,"updateTime":340,"relativeEntities":341,"slug":342,"properties":343,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"c89feeee-db0a-45fa-8127-c3688afadd5a","2024-01-12T18:13:42.864+00:00","2024-10-07T08:13:07.056+00:00",[],"Laboratory-of-Pharmaceutical-Technology-Ghent-University-Ghent-Belgium",{"title":344},{"VI":345},"Laboratory of Pharmaceutical Technology, Ghent University, Ghent, Belgium",{"title":347},{"VI":348},"Lieselotte De Smet",{"id":350,"sortIndex":191,"researcher":18,"roles":351,"affiliations":352,"properties":358},"7ccee323-8f22-46ec-81ec-11ddd445b894",[124],[353],{"id":18,"sortIndex":19,"affiliation":354,"properties":18},{"id":338,"createTime":339,"updateTime":340,"relativeEntities":355,"slug":342,"properties":356,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":357},{"VI":345},{"title":359},{"VI":360},"Chris Vervaet",{"id":362,"sortIndex":139,"researcher":18,"roles":363,"affiliations":364,"properties":373},"651eaeb3-fd07-4409-8129-601ea8def21b",[124],[365],{"id":18,"sortIndex":19,"affiliation":366,"properties":18},{"id":367,"createTime":368,"updateTime":368,"relativeEntities":369,"slug":18,"properties":370,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"7c099231-9f6c-4a7a-8c72-1e9cee47d592","2024-01-12T18:13:42.932+00:00",[],{"title":371},{"VI":372},"Laboratory of Medical Biochemistry and Clinical Analysis, Ghent University, Belgium",{"title":374},{"VI":375},"Jan Van Bocxlaer",{"id":377,"sortIndex":152,"researcher":18,"roles":378,"affiliations":379,"properties":385},"9f554809-6180-4761-b34e-7a4ded25b388",[124],[380],{"id":18,"sortIndex":19,"affiliation":381,"properties":18},{"id":306,"createTime":307,"updateTime":308,"relativeEntities":382,"slug":310,"properties":383,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":384},{"VI":313},{"title":386},{"VI":387},"Thomas De Beer",{"id":389,"sortIndex":122,"researcher":18,"roles":390,"affiliations":391,"properties":397},"1a633941-d24d-4d46-98ab-565e0e0fa26e",[124],[392],{"id":18,"sortIndex":19,"affiliation":393,"properties":18},{"id":323,"createTime":324,"updateTime":324,"relativeEntities":394,"slug":18,"properties":395,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":396},{"VI":328},{"title":398},{"VI":399},"Peter Adriaensens",{"id":401,"sortIndex":216,"researcher":18,"roles":402,"affiliations":403,"properties":409},"039aa203-26e3-4833-a7c7-c162666a22ab",[124],[404],{"id":18,"sortIndex":19,"affiliation":405,"properties":18},{"id":338,"createTime":339,"updateTime":340,"relativeEntities":406,"slug":342,"properties":407,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":408},{"VI":345},{"title":410},{"VI":411},"Jean Paul Remon",{"url":298,"publisher":413,"properties":435},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":414,"slug":10,"properties":415,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":418,"manageAffiliations":419,"indexDatabases":420,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":416,"title":417},{"VOID":13},{"EN":15},[],[],[421,428],{"id":78,"indexDatabase":422,"url":91,"indexYears":92,"academicFieldIds":427,"indexDatabaseRanking":97},{"id":80,"createTime":81,"updateTime":82,"relativeEntities":423,"label":424,"description":425,"key":88,"publicationTags":426,"standard":18},[],{"EN":85,"VI":85},{"EN":85,"VI":87},[90],[94,95,96],{"id":59,"indexDatabase":429,"url":74,"indexYears":18,"academicFieldIds":434,"indexDatabaseRanking":18},{"id":61,"createTime":62,"updateTime":63,"relativeEntities":430,"label":431,"description":432,"key":70,"publicationTags":433,"standard":18},[],{"EN":66,"VI":66},{"VI":68,"EN":69},[72,73],[76],{"volume":436,"pages":438},{"VOID":437},"87",{"VOID":439},"107-113","2014-05-01",2014,{"id":443,"createTime":444,"updateTime":445,"relativeEntities":446,"slug":447,"properties":448,"entityType":115,"verifyStatus":116,"verifyTime":445,"verifyNote":117,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":453,"fullTextUrl":18,"authors":454,"publicationType":253,"publisherRelationship":542,"citationCount":18,"citationInfo":18,"publishDate":570,"publishYear":571,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":284},"fe30e090-3e4d-412f-ad64-a5fb1cea2e91","2024-01-10T02:13:13.647+00:00","2025-02-13T23:56:46.234+00:00",[],"Hydrosoluble-polymers-for-muscular-gene-delivery",{"title":449,"doi":451},{"EN":450},"Hydrosoluble polymers for muscular gene delivery",{"VOID":452},"10.1016\u002Fj.ejpb.2008.11.006","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0939641108004451",[455,504,523],{"id":456,"sortIndex":19,"researcher":18,"roles":457,"affiliations":458,"properties":501},"5a34f864-9385-40eb-87c0-f6bf53cc3578",[124],[459,469,477,489],{"id":460,"sortIndex":152,"affiliation":461,"properties":468},"cbbff8a8-4a32-4132-8be1-7570254b522b",{"id":462,"createTime":463,"updateTime":463,"relativeEntities":464,"slug":18,"properties":465,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"1692fecf-b0c6-4343-a486-184eb042a6eb","2024-01-10T02:13:13.684+00:00",[],{"title":466},{"VI":467},"Inserm, Institut de Myologie, Paris, France",{},{"id":18,"sortIndex":19,"affiliation":470,"properties":18},{"id":471,"createTime":472,"updateTime":472,"relativeEntities":473,"slug":18,"properties":474,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"a9566446-636d-4b4a-83a7-d3070bab10f9","2023-11-30T17:32:14.606+00:00",[],{"title":475},{"VI":476},"Université Paris-Sud, Châtenay-Malabry, France",{"id":478,"sortIndex":242,"affiliation":479,"properties":488},"a2ab8b1d-4d98-43fd-8abb-68272f232450",{"id":480,"createTime":481,"updateTime":482,"relativeEntities":483,"slug":484,"properties":485,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"7258f12a-4973-4707-91e6-ac666e6022d9","2024-01-20T12:46:32.299+00:00","2024-12-26T23:06:22.178+00:00",[],"CNRS-Ch%C3%A2tenay-Malabry-France",{"title":486},{"VI":487},"CNRS, Châtenay-Malabry, France",{},{"id":490,"sortIndex":165,"affiliation":491,"properties":500},"12142b6c-7980-4927-ae44-3f8273d75c76",{"id":492,"createTime":493,"updateTime":494,"relativeEntities":495,"slug":496,"properties":497,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"01f73f23-6161-4881-82fb-15575638214e","2023-12-12T22:17:24.020+00:00","2025-06-11T15:23:55.491+00:00",[],"UPMC-Universit%C3%A9-Paris-06-Paris-France",{"title":498},{"VI":499},"UPMC Université Paris 06, Paris, France",{},{"title":502},{"VI":503},"Caroline Roques",{"id":505,"sortIndex":242,"researcher":18,"roles":506,"affiliations":507,"properties":520},"104a133d-2bf4-43c8-93aa-4c89a26415a8",[124],[508,515],{"id":509,"sortIndex":242,"affiliation":510,"properties":514},"a8dd5048-0907-476e-ac22-03f2231aba67",{"id":492,"createTime":493,"updateTime":494,"relativeEntities":511,"slug":496,"properties":512,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":513},{"VI":499},{},{"id":18,"sortIndex":19,"affiliation":516,"properties":18},{"id":462,"createTime":463,"updateTime":463,"relativeEntities":517,"slug":18,"properties":518,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":519},{"VI":467},{"title":521},{"VI":522},"Yves Fromes",{"id":524,"sortIndex":152,"researcher":18,"roles":525,"affiliations":526,"properties":539},"4d31deb2-b686-4cae-be28-aa66f339da08",[124],[527,532],{"id":18,"sortIndex":19,"affiliation":528,"properties":18},{"id":471,"createTime":472,"updateTime":472,"relativeEntities":529,"slug":18,"properties":530,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":531},{"VI":476},{"id":533,"sortIndex":242,"affiliation":534,"properties":538},"32c62f18-33f1-40b1-99c3-f3f5d6983441",{"id":480,"createTime":481,"updateTime":482,"relativeEntities":535,"slug":484,"properties":536,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":537},{"VI":487},{},{"title":540},{"VI":541},"Elias Fattal",{"url":453,"publisher":543,"properties":565},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":544,"slug":10,"properties":545,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":548,"manageAffiliations":549,"indexDatabases":550,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":546,"title":547},{"VOID":13},{"EN":15},[],[],[551,558],{"id":78,"indexDatabase":552,"url":91,"indexYears":92,"academicFieldIds":557,"indexDatabaseRanking":97},{"id":80,"createTime":81,"updateTime":82,"relativeEntities":553,"label":554,"description":555,"key":88,"publicationTags":556,"standard":18},[],{"EN":85,"VI":85},{"EN":85,"VI":87},[90],[94,95,96],{"id":59,"indexDatabase":559,"url":74,"indexYears":18,"academicFieldIds":564,"indexDatabaseRanking":18},{"id":61,"createTime":62,"updateTime":63,"relativeEntities":560,"label":561,"description":562,"key":70,"publicationTags":563,"standard":18},[],{"EN":66,"VI":66},{"VI":68,"EN":69},[72,73],[76],{"volume":566,"pages":568},{"VOID":567},"72",{"VOID":569},"378-390","2009-06-01",2009,{"id":573,"createTime":574,"updateTime":574,"relativeEntities":575,"slug":18,"properties":576,"entityType":115,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":583,"fullTextUrl":18,"authors":584,"publicationType":253,"publisherRelationship":644,"citationCount":18,"citationInfo":18,"publishDate":672,"publishYear":673,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":284},"1d2c83f6-b7ab-4605-bb24-eb402b561dd7","2023-12-06T23:56:27.206+00:00",[],{"references":577,"title":579,"doi":581},{"VOID":578},"Georgetti, 2008, Evaluation of in vivo efficacy of topical formulations containing soybean extract, Int. J. Pharm., 352, 189, 10.1016\u002Fj.ijpharm.2007.10.037\nBouwstra, 2002, Skin structure and mode of action of vesicles, Adv. Drug Deliv. Rev., 54, S41, 10.1016\u002FS0169-409X(02)00114-X\nCevc, 2004, Lipid vesicles and other colloids as drug carriers on the skin, Adv. Drug Deliv. Rev., 56, 675, 10.1016\u002Fj.addr.2003.10.028\nPrausnitz, 2004, Current status and future potential of transdermal drug delivery, Nat. Rev. Drug Discov., 3, 115, 10.1038\u002Fnrd1304\nHeurtault, 2002, A novel phase inversion-based process for the preparation of lipid nanocarriers, Pharm. Res., 19, 875, 10.1023\u002FA:1016121319668\nLamprecht, 2002, New lipid nanocapsules exhibit sustained release properties for amiodarone, J. Controlled Release, 84, 59, 10.1016\u002FS0168-3659(02)00258-4\nLamprecht, 2004, Lipid nanocarriers as drug delivery system for ibuprofen in pain treatment, Int. J. Pharm., 278, 407, 10.1016\u002Fj.ijpharm.2004.03.018\nPeltier, 2006, Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules, Pharm. Res., 23, 1243, 10.1007\u002Fs11095-006-0022-2\nAllard, 2008, Lipid nanocapsules loaded with an organometallic tamoxifen derivative as a novel drug-carrier system for experimental malignant gliomas, J. Controlled Release, 130, 146, 10.1016\u002Fj.jconrel.2008.05.027\nBéduneau, 2008, Brain targeting using novel lipid nanovectors, J. Controlled Release, 126, 44, 10.1016\u002Fj.jconrel.2007.11.001\nKhalid, 2006, Long circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors, Pharm. Res., 23, 752, 10.1007\u002Fs11095-006-9662-5\nLamprecht, 2006, Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition, J. Controlled Release, 112, 208, 10.1016\u002Fj.jconrel.2006.02.014\nBeduneau, 2007, Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab’ fragments, Biomaterials, 28, 4978, 10.1016\u002Fj.biomaterials.2007.05.014\nAnton, 2009, Aqueous-core lipid nanocapsules for encapsulating fragile hydrophilic and\u002For lipophilic molecules, Langmuir, 25, 11413, 10.1021\u002Fla901565q\nSchäfer-Korting, 2007, Lipid nanoparticles for improved topical application of drugs for skin diseases, Adv. Drug Deliv. Rev., 59, 427, 10.1016\u002Fj.addr.2007.04.006\nMüller, 2007, Nanostructured lipid carriers (NLC) in cosmetic dermal products, Adv. Drug Deliv. Rev., 59, 522, 10.1016\u002Fj.addr.2007.04.012\nRadomska-Soukharev, 2007, Stability of lipid excipients in solid lipid nanoparticles, Adv. Drug Deliv. Rev., 59, 411, 10.1016\u002Fj.addr.2007.04.004\nCasadei, 2006, Solid lipid nanoparticles incorporated in dextran hydrogels: a new drug delivery system for oral formulations, Int. J. Pharm., 325, 140, 10.1016\u002Fj.ijpharm.2006.06.012\nLi, 2008, A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers, Int. J. Pharm., 363, 177, 10.1016\u002Fj.ijpharm.2008.07.017\nJacobi, 2005, Comparison of four different in vitro systems to study the reservoir capacity of the stratum corneum, J. Controlled Release, 103, 61, 10.1016\u002Fj.jconrel.2004.11.013\nSimon, 2000, The pig as an experimental animal model of percutaneous permeation in man: qualitative and quantitative observations—an overview, Skin Pharmacol. Appl. Skin Physiol., 13, 229, 10.1159\u002F000029928\nBenech-Kieffer, 2000, Percutaneous absorption of sunscreens in vitro: interspecies comparison, skin models and reproducibility aspects, Skin Pharmacol. Appl. Skin Physiol., 13, 324, 10.1159\u002F000029940\nSchmook, 2001, Comparison of human skin or epidermis models with human and animal skin in in-vitro percutaneous absorption, Int. J. Pharm., 215, 51, 10.1016\u002FS0378-5173(00)00665-7\nHadgraft, 2000, pH, pKa and dermal delivery, Int. J. Pharm., 200, 243, 10.1016\u002FS0378-5173(00)00402-6\nShokri, 2001, The effect of surfactants on the skin penetration of diazepam, Int. J. Pharm., 228, 99, 10.1016\u002FS0378-5173(01)00805-5\nBenson, 2005, Transdermal drug delivery: penetration enhancement techniques, Curr. Drug Deliv., 2, 23, 10.2174\u002F1567201052772915\nZhao, 2009, A dynamic topical hydrofluoroalkane foam to induce nanoparticle modification and drug release in situ, Eur. J. Pharm. Biopharm., 72, 521, 10.1016\u002Fj.ejpb.2009.03.002\nZhai, 2001, Effects of skin occlusion on percutaneous absorption: an overview, Skin Pharmacol. Appl., 14, 1, 10.1159\u002F000056328\nZellmer, 1995, Interaction of phosphatidylcholine liposomes with the human stratum corneum, Biochim. Biophys. Acta, 237, 176, 10.1016\u002F0005-2736(95)00100-H\nSinico, 2005, Liposomes as carriers for dermal delivery of tretinoin: in vitro evaluation of drug permeation and vesicle–skin interaction, J. Controlled Release, 103, 123, 10.1016\u002Fj.jconrel.2004.11.020\nMoser, 2001, Enhanced skin permeation of a lipophilic drug using supersaturated formulations, J. Controlled Release, 73, 245, 10.1016\u002FS0168-3659(01)00290-5\nWu, 2009, Drug delivery to the skin from sub-micron polymeric particle formulations: influence of particle size and polymer hydrophobicity, Pharm. Res., 26, 1995, 10.1007\u002Fs11095-009-9915-1\nCleek, 1993, A new method for estimating dermal absorption from chemical exposure. 1. General approach, Pharm. Res., 10, 497, 10.1023\u002FA:1018981515480",{"EN":580},"Lipid nanocapsules for dermal application: A comparative study of lipid-based versus polymer-based nanocarriers",{"VOID":582},"10.1016\u002Fj.ejpb.2011.04.009","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0939641111001512",[585,610,632],{"id":586,"sortIndex":152,"researcher":18,"roles":587,"affiliations":588,"properties":607},"73a6e531-e659-499e-9021-5ee8f0e4626d",[124],[589,597],{"id":18,"sortIndex":19,"affiliation":590,"properties":18},{"id":591,"createTime":592,"updateTime":592,"relativeEntities":593,"slug":18,"properties":594,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"ece924c9-4762-4b14-85ed-7af5b38e4f42","2023-12-06T23:56:27.239+00:00",[],{"title":595},{"VI":596},"Laboratory of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, Bonn, Germany",{"id":598,"sortIndex":242,"affiliation":599,"properties":606},"255dd4e8-6c38-4a9c-9995-15d9086959d4",{"id":600,"createTime":601,"updateTime":601,"relativeEntities":602,"slug":18,"properties":603,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"b92a5819-e3d1-47b0-a876-adbc0b7fc2d6","2024-02-10T14:28:18.639+00:00",[],{"title":604},{"VI":605},"Laboratory of Pharmaceutical Engineering, University of Franche-Comté, Besançon, France",{},{"title":608},{"VI":609},"Alf Lamprecht",{"id":611,"sortIndex":19,"researcher":18,"roles":612,"affiliations":613,"properties":629},"0fe6503d-b790-47f0-932c-4609f9c9ea92",[124],[614,619],{"id":18,"sortIndex":19,"affiliation":615,"properties":18},{"id":591,"createTime":592,"updateTime":592,"relativeEntities":616,"slug":18,"properties":617,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":618},{"VI":596},{"id":620,"sortIndex":242,"affiliation":621,"properties":628},"3174b18f-75d8-4088-9d39-7aa7acd9add9",{"id":622,"createTime":623,"updateTime":623,"relativeEntities":624,"slug":18,"properties":625,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"aa0bdf29-695c-46a1-8984-0f3addda3762","2023-12-06T23:56:27.226+00:00",[],{"title":626},{"VI":627},"Department of Drug Technology, Ain Shams University, Cairo, Egypt",{},{"title":630},{"VI":631},"Mona M.A. Abdel-Mottaleb",{"id":633,"sortIndex":242,"researcher":18,"roles":634,"affiliations":635,"properties":641},"06fca2ba-ea47-4088-ae25-2b1de285a54e",[124],[636],{"id":18,"sortIndex":19,"affiliation":637,"properties":18},{"id":591,"createTime":592,"updateTime":592,"relativeEntities":638,"slug":18,"properties":639,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":640},{"VI":596},{"title":642},{"VI":643},"Dirk Neumann",{"url":583,"publisher":645,"properties":667},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":646,"slug":10,"properties":647,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":650,"manageAffiliations":651,"indexDatabases":652,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":648,"title":649},{"VOID":13},{"EN":15},[],[],[653,660],{"id":78,"indexDatabase":654,"url":91,"indexYears":92,"academicFieldIds":659,"indexDatabaseRanking":97},{"id":80,"createTime":81,"updateTime":82,"relativeEntities":655,"label":656,"description":657,"key":88,"publicationTags":658,"standard":18},[],{"EN":85,"VI":85},{"EN":85,"VI":87},[90],[94,95,96],{"id":59,"indexDatabase":661,"url":74,"indexYears":18,"academicFieldIds":666,"indexDatabaseRanking":18},{"id":61,"createTime":62,"updateTime":63,"relativeEntities":662,"label":663,"description":664,"key":70,"publicationTags":665,"standard":18},[],{"EN":66,"VI":66},{"VI":68,"EN":69},[72,73],[76],{"volume":668,"pages":670},{"VOID":669},"79",{"VOID":671},"36-42","2011-09-01",2011,{"id":675,"createTime":676,"updateTime":677,"relativeEntities":678,"slug":679,"properties":680,"entityType":115,"verifyStatus":116,"verifyTime":677,"verifyNote":117,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":687,"fullTextUrl":18,"authors":688,"publicationType":253,"publisherRelationship":804,"citationCount":18,"citationInfo":18,"publishDate":832,"publishYear":441,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":284},"e24de3aa-3d62-467a-81be-3968016d6684","2024-02-12T06:50:11.003+00:00","2024-09-22T23:55:46.162+00:00",[],"Digoxin-net-secretory-transport-in-bronchial-epithelial-cell-layers-is-not-exclusively-mediated-by-P-glycoprotein-MDR1",{"references":681,"title":683,"doi":685},{"VOID":682},"Bosquillon, 2010, Drug transporters in the lung – do they play a role in the biopharmaceutics of inhaled drugs?, J. Pharm. Sci., 99, 2240, 10.1002\u002Fjps.21995\nForbes, 2011, Challenges in inhaled product development and opportunities for open innovation, Adv. Drug. Deliv. Rev., 63, 69, 10.1016\u002Fj.addr.2010.11.004\nSporty, 2008, In vitro cell culture models for the assessment of pulmonary drug disposition, Expert. Opin. Drug. Metab. Toxicol., 4, 333, 10.1517\u002F17425255.4.4.333\nForbes, 2005, Human respiratory epithelial cell culture for drug delivery applications, Eur. J. Pharm. Biopharm., 60, 193, 10.1016\u002Fj.ejpb.2005.02.010\nGrainger, 2006, Culture of Calu-3 cells at the air interface provides a representative model of the airway epithelial barrier, Pharm. Res., 23, 1482, 10.1007\u002Fs11095-006-0255-0\nLin, 2007, Air–liquid interface (ALI) culture of human bronchial epithelial cell monolayers as an in vitro model for airway drug transport studies, J. Pharm. Sci., 96, 341, 10.1002\u002Fjps.20803\nMukherjee, 2012, Evaluation of air-interfaced Calu-3 cell layers for investigation of inhaled drug interactions with organic cation transporters in vitro, Int. J. Pharm., 426, 7, 10.1016\u002Fj.ijpharm.2011.12.036\nMamlouk, 2013, Salbutamol sulfate absorption across Calu-3 bronchial epithelia cell monolayer is inhibited in the presence of common anionic NSAIDs, J. Asthma, 50, 334, 10.3109\u002F02770903.2013.773518\nH.X. Ong, D. Traini, M. Bebawy, P.M. Young, Ciprofloxacin is actively transported across bronchial lung epithelial using a Calu-3 air-interface cell model, Antimicrob. Agents Chemother. (2013) (March 18) (Epub ahead of print).\nGlaeser, 2011, Importance of P-glycoprotein for drug–drug interactions, Handb. Exp. Pharmacol., 201, 285, 10.1007\u002F978-3-642-14541-4_7\nUrquhart, 2009, Blood–brain barrier transporters and response to CNS-active drugs, Eur. J. Clin. Pharmacol., 65, 1063, 10.1007\u002Fs00228-009-0714-8\nBleasby, 2006, Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition, Xenobiotica, 36, 963, 10.1080\u002F00498250600861751\nMadlova, 2009, In-vitro respiratory drug absorption models possess nominal functional P-glycoprotein activity, J. Pharm. Pharmacol., 61, 293, 10.1211\u002Fjpp.61.03.0003\nHaghi, 2010, Time- and passage-dependent characteristics of a Calu-3 respiratory epithelial cell model, Drug. Dev. Ind. Pharm., 36, 1207, 10.3109\u002F03639041003695113\nRautio, 2006, In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates, Drug Metab. Dispos., 34, 786, 10.1124\u002Fdmd.105.008615\nHuang, 2007, Drug interaction studies: study design, data analysis, and implications for dosing and labeling, Clin. Pharmacol. Ther., 81, 298, 10.1038\u002Fsj.clpt.6100054\nManford, 2005, Drug permeability in 16HBE14o-airway cell layers correlates with absorption from the isolated perfused rat lung, Eur. J. Pharm. Sci., 26, 414, 10.1016\u002Fj.ejps.2005.07.010\nSmith, 2000, MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping, J. Biol. Chem., 275, 23530, 10.1074\u002Fjbc.M909002199\nKullak-Ublick, 2001, Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver, Gastroenterology, 120, 525, 10.1053\u002Fgast.2001.21176\nMikkaichi, 2004, Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney, Proc. Natl. Acad. Sci. USA, 101, 3569, 10.1073\u002Fpnas.0304987101\nYamaguchi, 2010, Transport of estrone 3-sulfate mediated by organic anion transporter OATP4C1: estrone 3-sulfate binds to the different recognition site for digoxin in OATP4C1, Drug Metab. Pharmacokinet., 25, 314, 10.2133\u002Fdmpk.25.314\nKimoto, 2011, Characterization of digoxin uptake in sandwich-cultured human hepatocytes, Drug Metab. Dispos., 39, 47, 10.1124\u002Fdmd.110.034298\nTaub, 2011, Digoxin is not a substrate for organic anion transporting polypeptide transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but is a substrate for a sodium dependent transporter expressed in HEK293 Cells, Drug Metab. Dispos., 39, 2093, 10.1124\u002Fdmd.111.040816\nWang, 2008, Application and limitation of inhibitors in drug-transporter interactions studies, Int. J. Pharm., 356, 12, 10.1016\u002Fj.ijpharm.2007.12.024\nMease, 2012, Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2, J. Pharm. Sci., 101, 1888, 10.1002\u002Fjps.23069\nHilgendorf, 2007, Expression of thrity-six drug transporter genes in human intestine, liver, kidney and organotypic cell lines, Drug Metab. Dispos., 35, 1333, 10.1124\u002Fdmd.107.014902\nMechetner, 1997, P-glycoprotein function involves conformational transitions detectable by differential immunoreactivity, Proc. Natl. Acad. Sci. USA, 94, 12908, 10.1073\u002Fpnas.94.24.12908\nEndter, 2009, RT-PCR analysis of ABC, SLC and SLCO drug transporters in human lung epithelial cell models, J. Pharm. Pharmacol., 61, 583, 10.1211\u002Fjpp.61.05.0006\nKuteykin-Teplyakov, 2010, Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport, Br. J. Pharmacol., 160, 1453, 10.1111\u002Fj.1476-5381.2010.00801.x\nPark, 2003, Analysis of P-glycoprotein-mediated membrane transport in human peripheral blood lymphocytes using the UIC2 shift assay, Cytometry A, 53, 67, 10.1002\u002Fcyto.a.10039\nMechetner, 2007, Detection of the MDR1 P-glycoprotein expression and function, Methods Mol. Biol., 378, 175, 10.1007\u002F978-1-59745-323-3_13\nZhou, 2008, Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development, Curr. Med. Chem., 15, 1981, 10.2174\u002F092986708785132870\nLowes, 2003, Evidence for a non-MDR1 component in digoxin secretion by human intestinal Caco-2 epithelial layers, Eur. J. Pharmacol., 458, 49, 10.1016\u002FS0014-2999(02)02764-4\nHamilton, 2001, P-glycoprotein efflux pump expression and activity in Calu-3 cells, J. Pharm. Sci., 90, 647, 10.1002\u002F1520-6017(200105)90:5\u003C647::AID-JPS1021>3.0.CO;2-G\nScheffer, 2002, Multidrug resistance related molecules in human and murine lung, J. Clin. Pathol., 55, 332, 10.1136\u002Fjcp.55.5.332\nGribar, 2000, Functional characterization of glycosylation-deficient human P-glycoprotein using a vaccinia virus expression system, J. Membr. Biol., 173, 203, 10.1007\u002Fs002320001020\nSereš, 2011, Tunicamycin depresses p-glycoprotein glycosylation without an effect on its membrane localization and drug efflux activity in l1210 cells, Int. J. Mol. Sci., 12, 7772, 10.3390\u002Fijms12117772\nDraheim, 2010, N-glycosylation of ABC transporters is associated with functional activity in sandwich-cultured rat hepatocytes, Eur. J. Pharm. Sci., 41, 201, 10.1016\u002Fj.ejps.2010.06.005\nMolnár, 2009, Interaction of tomato lectin with ABC transporter in cancer cells: glycosylation confers functional conformation of P-gp, Acta Histochem., 111, 329, 10.1016\u002Fj.acthis.2008.11.010\nKramer, 1995, Inhibition of N-linked glycosylation of P-glycoprotein by tunicamycin results in a reduced multidrug resistance phenotype, Br. J. Cancer, 71, 670, 10.1038\u002Fbjc.1995.133\nGoda, 2007, Complete inhibition of P-glycoprotein by simultaneous treatment with a distinct class of modulators and the UIC2 monoclonal antibody, J. Pharmacol. Exp. Ther., 320, 81, 10.1124\u002Fjpet.106.110155\nLetschert, 2005, Vectorial transport of the peptide CCK-8 by double-transfected MDCKII cells stably expressing the organic anion transporter OATP1B3 (OATP8) and the export pump ABCC2, J. Pharmacol. Exp. Therapy, 313, 356, 10.1124\u002Fjpet.104.081224\nLetschert, 2006, Molecular characterization and inhibition of amanitin uptake into human hepatocytes, Toxicol. Sci., 91, 140, 10.1093\u002Ftoxsci\u002Fkfj141\nChilds, 1998, Taxol resistance mediated by transfection of the liver-specific sister gene of P-glycoprotein, Cancer Res., 58, 4160\nBöhme, 1993, Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane, FEBS Lett., 333, 193, 10.1016\u002F0014-5793(93)80403-H\nBourasset, 2003, Evidence for an active transport of morphine-6-beta-d-glucuronide but not P-glycoprotein-mediated at the blood-brain barrier, J. Neurochem., 86, 1564, 10.1046\u002Fj.1471-4159.2003.01990.x\nAcharya, 2008, Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells, Drug Metab. Dispos., 36, 452, 10.1124\u002Fdmd.107.017301\nPeters, 2011, Oral absorption of clarithromycin is nearly abolished by chronic comedication of rifampicin in foals, Drug Metab. Dispos., 39, 1643, 10.1124\u002Fdmd.111.039206",{"EN":684},"Digoxin net secretory transport in bronchial epithelial cell layers is not exclusively mediated by P-glycoprotein\u002FMDR1",{"VOID":686},"10.1016\u002Fj.ejpb.2013.06.010","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0939641113002294",[689,706,721,736,751,763,775,792],{"id":690,"sortIndex":139,"researcher":18,"roles":691,"affiliations":692,"properties":703},"6314eaed-649e-48f0-b594-aa74476198b5",[124],[693],{"id":18,"sortIndex":19,"affiliation":694,"properties":18},{"id":695,"createTime":696,"updateTime":697,"relativeEntities":698,"slug":699,"properties":700,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"ab2dcf66-03c9-40a6-b003-91c9e3169528","2024-01-24T12:36:48.740+00:00","2024-08-31T20:03:58.419+00:00",[],"AstraZeneca-R-D-Charnwood-Loughborough-UK",{"title":701},{"VI":702},"AstraZeneca R&D Charnwood, Loughborough, UK",{"title":704},{"VI":705},"Vanessa Zann",{"id":707,"sortIndex":191,"researcher":18,"roles":708,"affiliations":709,"properties":718},"c4860381-df89-47cc-b855-5eec173fca4c",[124],[710],{"id":18,"sortIndex":19,"affiliation":711,"properties":18},{"id":712,"createTime":713,"updateTime":713,"relativeEntities":714,"slug":18,"properties":715,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"92fdc18e-18aa-4647-b62e-5631309a374b","2024-01-26T17:30:16.963+00:00",[],{"title":716},{"VI":717},"Immune Modulation Group, Division of Molecular and Cellular Science, School of Pharmacy, University of Nottingham, UK",{"title":719},{"VI":720},"David I. Pritchard",{"id":722,"sortIndex":242,"researcher":18,"roles":723,"affiliations":724,"properties":733},"c185684a-1229-446c-a6ac-bb5cceeb4494",[124],[725],{"id":18,"sortIndex":19,"affiliation":726,"properties":18},{"id":727,"createTime":728,"updateTime":728,"relativeEntities":729,"slug":18,"properties":730,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"1cb2a172-372c-4773-9183-2538950316ca","2024-02-12T06:50:11.216+00:00",[],{"title":731},{"VI":732},"Allergy Research Group, School of Molecular Medical Sciences, University of Nottingham, UK",{"title":734},{"VI":735},"David Y.S. Chau",{"id":737,"sortIndex":216,"researcher":18,"roles":738,"affiliations":739,"properties":748},"de43a137-ab72-4f22-b7fb-8fff5a6690c4",[124],[740],{"id":18,"sortIndex":19,"affiliation":741,"properties":18},{"id":742,"createTime":743,"updateTime":743,"relativeEntities":744,"slug":18,"properties":745,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"b5030126-3d73-469a-9678-ba3a9a04dbb9","2024-01-26T17:30:16.989+00:00",[],{"title":746},{"VI":747},"Division of Drug Delivery and Tissue Engineering, School of Pharmacy, University of Nottingham, UK",{"title":749},{"VI":750},"Cynthia Bosquillon",{"id":752,"sortIndex":165,"researcher":18,"roles":753,"affiliations":754,"properties":760},"9874209e-deb1-49e9-a465-a1e5cd0d3e70",[124],[755],{"id":18,"sortIndex":19,"affiliation":756,"properties":18},{"id":712,"createTime":713,"updateTime":713,"relativeEntities":757,"slug":18,"properties":758,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":759},{"VI":717},{"title":761},{"VI":762},"Alan Brown",{"id":764,"sortIndex":19,"researcher":18,"roles":765,"affiliations":766,"properties":772},"0fbdd833-ecc9-4c93-8faa-46e0eaf43be4",[124],[767],{"id":18,"sortIndex":19,"affiliation":768,"properties":18},{"id":742,"createTime":743,"updateTime":743,"relativeEntities":769,"slug":18,"properties":770,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":771},{"VI":747},{"title":773},{"VI":774},"Victoria Hutter",{"id":776,"sortIndex":152,"researcher":18,"roles":777,"affiliations":778,"properties":789},"720b4408-24f4-4f03-bdb6-276cf1578925",[124],[779],{"id":18,"sortIndex":19,"affiliation":780,"properties":18},{"id":781,"createTime":782,"updateTime":783,"relativeEntities":784,"slug":785,"properties":786,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"98eab264-6706-4b43-8080-1b3c648b7951","2024-01-09T03:20:03.713+00:00","2025-01-07T15:26:32.633+00:00",[],"AstraZeneca-R-D-M%C3%B6lndal-Sweden",{"title":787},{"VI":788},"AstraZeneca R&D, Mölndal, Sweden",{"title":790},{"VI":791},"Constanze Hilgendorf",{"id":793,"sortIndex":122,"researcher":18,"roles":794,"affiliations":795,"properties":801},"8ca879f5-dd7b-4770-885d-9f1fc573ef66",[124],[796],{"id":18,"sortIndex":19,"affiliation":797,"properties":18},{"id":695,"createTime":696,"updateTime":697,"relativeEntities":798,"slug":699,"properties":799,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":800},{"VI":702},{"title":802},{"VI":803},"Anne Cooper",{"url":687,"publisher":805,"properties":827},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":806,"slug":10,"properties":807,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":810,"manageAffiliations":811,"indexDatabases":812,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":808,"title":809},{"VOID":13},{"EN":15},[],[],[813,820],{"id":78,"indexDatabase":814,"url":91,"indexYears":92,"academicFieldIds":819,"indexDatabaseRanking":97},{"id":80,"createTime":81,"updateTime":82,"relativeEntities":815,"label":816,"description":817,"key":88,"publicationTags":818,"standard":18},[],{"EN":85,"VI":85},{"EN":85,"VI":87},[90],[94,95,96],{"id":59,"indexDatabase":821,"url":74,"indexYears":18,"academicFieldIds":826,"indexDatabaseRanking":18},{"id":61,"createTime":62,"updateTime":63,"relativeEntities":822,"label":823,"description":824,"key":70,"publicationTags":825,"standard":18},[],{"EN":66,"VI":66},{"VI":68,"EN":69},[72,73],[76],{"volume":828,"pages":830},{"VOID":829},"86",{"VOID":831},"74-82","2014-01-01",{"id":834,"createTime":835,"updateTime":836,"relativeEntities":837,"slug":838,"properties":839,"entityType":115,"verifyStatus":116,"verifyTime":836,"verifyNote":117,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":846,"fullTextUrl":18,"authors":847,"publicationType":253,"publisherRelationship":942,"citationCount":18,"citationInfo":18,"publishDate":970,"publishYear":971,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":284},"0900866c-6437-4ab6-a357-ee4073b9fd95","2024-02-11T22:22:34.296+00:00","2025-01-27T23:55:31.740+00:00",[],"Modulation-of-immune-response-and-enhanced-clearance-of-Salmonella-typhi-by-delivery-of-Vi-polysaccharide-conjugate-using-PLA-nanoparticles",{"references":840,"title":842,"doi":844},{"VOID":841},"Gonzalez-Fernandez, 2008, Immune responses to polysaccharides: lessons from humans and mice, Vaccine, 26, 292, 10.1016\u002Fj.vaccine.2007.11.042\nPoolman, 2011, Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines, Expert Rev. Vaccines, 10, 307, 10.1586\u002Ferv.11.8\nVakevainen, 2010, Serotype-specific hyporesponsiveness to pneumococcal conjugate vaccine in infants carrying pneumococcus at the time of vaccination, J. Pediatr., 157, 778, 10.1016\u002Fj.jpeds.2010.04.071\nDagan, 2010, Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy, J. Infect. Dis., 201, 1570, 10.1086\u002F652006\nAstronomo, 2010, Carbohydrate vaccines: developing sweet solutions to sticky situations?, Nat. Rev. Drug Discov., 9, 308, 10.1038\u002Fnrd3012\nObukhanych, 2006, T-independent type II immune responses generate memory B cells, J. Exp. Med., 203, 305, 10.1084\u002Fjem.20052036\nWeintraub, 2003, Immunology of bacterial polysaccharide antigens, Carbohydr. Res., 338, 2539, 10.1016\u002Fj.carres.2003.07.008\nGuttormsen, 1999, Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines, Infect. Immun., 67, 6375, 10.1128\u002FIAI.67.12.6375-6384.1999\nAvci, 2011, A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design, Nat. Med., 17, 1602, 10.1038\u002Fnm.2535\nRappuoli, 2018, Glycoconjugate vaccines: Principles and mechanisms, Sci. Transl. Med., 10, 10.1126\u002Fscitranslmed.aat4615\nAdamo, 2017, Advancing Homogeneous Antimicrobial Glycoconjugate Vaccines, Acc. Chem. Res., 50, 1270, 10.1021\u002Facs.accounts.7b00106\nGoldblatt, 2009, The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50–80 years, Clin. Infect. Dis., 49, 1318, 10.1086\u002F606046\nGreenberg, 2014, Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60–64 years of age, Vaccine, 32, 2364, 10.1016\u002Fj.vaccine.2014.02.002\nMusher, 2016, Why the recent ACIP recommendations regarding conjugate pneumococcal vaccine in adults may be irrelevant, Hum. Vaccin. Immunother., 12, 331, 10.1080\u002F21645515.2015.1098794\nJuergens, 2014, Hum. Vaccin. Immunother., 10, 1343, 10.4161\u002Fhv.27998\nFlebbe, 1986, Immunopotentiating effects of the adjuvants SGP and Quil A. I. Antibody responses to T-dependent and T-independent antigens, Cell. Immunol., 99, 119, 10.1016\u002F0008-8749(86)90221-2\nWuorimaa, 2001, Tolerability and immunogenicity of an eleven-valent pneumococcal conjugate vaccine in healthy toddlers, Pediatr. Infect. Dis. J., 20, 272, 10.1097\u002F00006454-200103000-00011\nHaas, 2011, Programmed cell death 1 suppresses B-1b cell expansion and long-lived IgG production in response to T cell-independent type 2 antigens, J. Immunol., 187, 5183, 10.4049\u002Fjimmunol.1101990\nSouvannavong, 2004, Lipopolysaccharide protects primary B lymphocytes from apoptosis by preventing mitochondrial dysfunction and bax translocation to mitochondria, Infect. Immun., 72, 3260, 10.1128\u002FIAI.72.6.3260-3266.2004\nCirelli, 2019, Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance, Cell, 177, 1153, 10.1016\u002Fj.cell.2019.04.012\nWorld Health, O., 2019, Typhoid vaccines: WHO position paper, March 2018 - Recommendations, Vaccine, 37, 214, 10.1016\u002Fj.vaccine.2018.04.022\nJiang, 2005, Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens, Adv. Drug Deliv. Rev., 57, 391, 10.1016\u002Fj.addr.2004.09.003\nPavot, 2014, Poly(lactic acid) and poly(lactic-co-glycolic acid) particles as versatile carrier platforms for vaccine delivery, Nanomedicine (Lond), 9, 2703, 10.2217\u002Fnnm.14.156\nSilva, 2016, PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity, Hum. Vaccin. Immunother., 12, 1056, 10.1080\u002F21645515.2015.1117714\nKanchan, 2007, Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response, Biomaterials, 28, 5344, 10.1016\u002Fj.biomaterials.2007.08.015\nKanchan, 2009, Memory antibody response from antigen loaded polymer particles and the effect of antigen release kinetics, Biomaterials, 30, 4763, 10.1016\u002Fj.biomaterials.2009.05.075\nAnish, 2012, The immunogenic characteristics associated with multivalent display of Vi polysaccharide antigen using biodegradable polymer particles, Biomaterials, 33, 6843, 10.1016\u002Fj.biomaterials.2012.06.007\nAnish, 2014, Delivery of polysaccharides using polymer particles: implications on size-dependent immunogenicity, opsonophagocytosis, and protective immunity, Mol. Pharm., 11, 922, 10.1021\u002Fmp400589q\nPeres, 2017, Poly(lactic acid)-based particulate systems are promising tools for immune modulation, Acta Biomater., 48, 41, 10.1016\u002Fj.actbio.2016.11.012\nMicoli, 2011, Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi, Vaccine, 29, 712, 10.1016\u002Fj.vaccine.2010.11.022\nMicoli, 2012, Production of a conjugate vaccine for Salmonella enterica serovar Typhi from Citrobacter Vi, Vaccine, 30, 853, 10.1016\u002Fj.vaccine.2011.11.108\nPanda, 2016, Formulation and characterization of clozapine and risperidone co-entrapped spray-dried PLGA nanoparticles, Pharm. Dev. Technol., 21, 43, 10.3109\u002F10837450.2014.965324\nSmith, 1985, Measurement of protein using bicinchoninic acid, Anal. Biochem., 150, 76, 10.1016\u002F0003-2697(85)90442-7\nReddy, 2006, In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles, J. Control. Release, 112, 26, 10.1016\u002Fj.jconrel.2006.01.006\nSmith, 2014, The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFalpha, Cancer Discov, 4, 1214, 10.1158\u002F2159-8290.CD-13-1007\nLink, 2012, Innate immunity mediates follicular transport of particulate but not soluble protein antigen, J. Immunol., 188, 3724, 10.4049\u002Fjimmunol.1103312\nRostami, 2017, Co-utilization of a TLR5 agonist and nano-formulation of HIV-1 vaccine candidate leads to increased vaccine immunogenicity and decreased immunogenic dose: A preliminary study, Immunol. Lett., 187, 19, 10.1016\u002Fj.imlet.2017.05.002\nReddy, 2007, Exploiting lymphatic transport and complement activation in nanoparticle vaccines, Nat. Biotechnol., 25, 1159, 10.1038\u002Fnbt1332\nHanson, 2015, Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants, J Clin Invest, 125, 2532, 10.1172\u002FJCI79915\nGarg, 2010, Hemoglobin transforms anti-inflammatory Salmonella typhi virulence polysaccharide into a TLR-2 agonist, J. Immunol., 184, 5980, 10.4049\u002Fjimmunol.0903512\nKim, 2017, Synthetic vaccine nanoparticles target to lymph node triggering enhanced innate and adaptive antitumor immunity, Biomaterials, 130, 56, 10.1016\u002Fj.biomaterials.2017.03.034\nGupta, 2014, Flagellin a toll-like receptor 5 agonist as an adjuvant in chicken vaccines, Clin. Vaccine Immunol., 21, 261, 10.1128\u002FCVI.00669-13\nWiedinger, 2017, Utilization of cholera toxin B as a mucosal adjuvant elicits antibody-mediated protection against S. pneumoniae infection in mice, Ther. Adv. Vaccines, 5, 15, 10.1177\u002F2051013617691041\nJohnson, 2014, Gamma interferon: from antimicrobial activity to immune regulation, Front. Immunol., 5, 667\nKaiko, 2008, Immunological decision-making: how does the immune system decide to mount a helper T-cell response?, Immunology, 123, 326, 10.1111\u002Fj.1365-2567.2007.02719.x\nBegg, 2011, Does a Th1 over Th2 dominancy really exist in the early stages of Mycobacterium avium subspecies paratuberculosis infections?, Immunobiology, 216, 840, 10.1016\u002Fj.imbio.2010.12.004\nSnapper, 1992, Induction of IgG3 secretion by interferon gamma: a model for T cell-independent class switching in response to T cell-independent type 2 antigens, J. Exp. Med., 175, 1367, 10.1084\u002Fjem.175.5.1367\nHussain, 1999, Selective correlation of interferon-gamma, tumour necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor with immunoglobulin G1 and immunoglobulin G3 subclass antibody in leprosy, Immunology, 98, 238, 10.1046\u002Fj.1365-2567.1999.00876.x\nMawas, 2000, Serotype of Streptococcus pneumoniae capsular polysaccharide can modify the Th1\u002FTh2 cytokine profile and IgG subclass response to pneumococal-CRM(197) conjugate vaccines in a murine model, Vaccine, 19, 1159, 10.1016\u002FS0264-410X(00)00314-5\nJefferis, 1990, Selective IgG subclass deficiency: quantification and clinical relevance, Clin. Exp. Immunol., 81, 357, 10.1111\u002Fj.1365-2249.1990.tb05339.x\nCampbell, 2010, Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity, Clin. Vaccine Immunol., 17, 840, 10.1128\u002FCVI.00529-09\nNaess, 1999, Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine, Vaccine, 17, 754, 10.1016\u002FS0264-410X(98)00259-X",{"EN":843},"Modulation of immune response and enhanced clearance of Salmonella typhi by delivery of Vi polysaccharide conjugate using PLA nanoparticles",{"VOID":845},"10.1016\u002Fj.ejpb.2020.05.023","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0939641120301508",[848,873,885,904,923],{"id":849,"sortIndex":242,"researcher":18,"roles":850,"affiliations":851,"properties":870},"a02ea491-c673-41ff-953f-dc0ccee1d4e5",[124],[852,860],{"id":18,"sortIndex":19,"affiliation":853,"properties":18},{"id":854,"createTime":855,"updateTime":855,"relativeEntities":856,"slug":18,"properties":857,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"d08840e3-ef24-4c8d-a24d-757b0d3244e0","2023-12-28T03:54:48.248+00:00",[],{"title":858},{"VI":859},"Product Development Cell, National Institute of Immunology, New Delhi, 110067, India",{"id":861,"sortIndex":242,"affiliation":862,"properties":869},"a87ff86d-28b0-4ce4-80b4-5ee629e060d5",{"id":863,"createTime":864,"updateTime":864,"relativeEntities":865,"slug":18,"properties":866,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"63d75186-da69-4a4f-9dba-12ff7cd0f2a9","2024-02-11T22:22:34.338+00:00",[],{"title":867},{"VI":868},"Center of Excellence in Vaccine Delivery, National Institute of Immunology, New Delhi 110067, India",{},{"title":871},{"VI":872},"Robin Kumar",{"id":874,"sortIndex":165,"researcher":18,"roles":875,"affiliations":876,"properties":882},"9ad95057-63f6-480f-adb0-b5d4355269ac",[124],[877],{"id":18,"sortIndex":19,"affiliation":878,"properties":18},{"id":863,"createTime":864,"updateTime":864,"relativeEntities":879,"slug":18,"properties":880,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":881},{"VI":868},{"title":883},{"VI":884},"Anees Ahmed",{"id":886,"sortIndex":19,"researcher":18,"roles":887,"affiliations":888,"properties":901},"099c201f-6e6f-4275-846b-b8ba3ca11c94",[124],[889,896],{"id":890,"sortIndex":242,"affiliation":891,"properties":895},"63097812-2572-4d39-a7bd-38be8029b292",{"id":863,"createTime":864,"updateTime":864,"relativeEntities":892,"slug":18,"properties":893,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":894},{"VI":868},{},{"id":18,"sortIndex":19,"affiliation":897,"properties":18},{"id":854,"createTime":855,"updateTime":855,"relativeEntities":898,"slug":18,"properties":899,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":900},{"VI":859},{"title":902},{"VI":903},"Jairam Meena",{"id":905,"sortIndex":152,"researcher":18,"roles":906,"affiliations":907,"properties":920},"bfd6a04c-8604-49fb-ac07-9840acd229fe",[124],[908,915],{"id":909,"sortIndex":242,"affiliation":910,"properties":914},"d645bf5e-315f-4803-9f47-7469e7290638",{"id":863,"createTime":864,"updateTime":864,"relativeEntities":911,"slug":18,"properties":912,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":913},{"VI":868},{},{"id":18,"sortIndex":19,"affiliation":916,"properties":18},{"id":854,"createTime":855,"updateTime":855,"relativeEntities":917,"slug":18,"properties":918,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":919},{"VI":859},{"title":921},{"VI":922},"Mamta Singh",{"id":924,"sortIndex":122,"researcher":18,"roles":925,"affiliations":926,"properties":939},"a318262a-211c-4509-a6c9-947953e30da1",[124],[927,934],{"id":928,"sortIndex":242,"affiliation":929,"properties":933},"b4380459-0c13-4f3c-b462-9095875882f4",{"id":863,"createTime":864,"updateTime":864,"relativeEntities":930,"slug":18,"properties":931,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":932},{"VI":868},{},{"id":18,"sortIndex":19,"affiliation":935,"properties":18},{"id":854,"createTime":855,"updateTime":855,"relativeEntities":936,"slug":18,"properties":937,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":938},{"VI":859},{"title":940},{"VI":941},"Amulya Kumar Panda",{"url":846,"publisher":943,"properties":965},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":944,"slug":10,"properties":945,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":948,"manageAffiliations":949,"indexDatabases":950,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":946,"title":947},{"VOID":13},{"EN":15},[],[],[951,958],{"id":78,"indexDatabase":952,"url":91,"indexYears":92,"academicFieldIds":957,"indexDatabaseRanking":97},{"id":80,"createTime":81,"updateTime":82,"relativeEntities":953,"label":954,"description":955,"key":88,"publicationTags":956,"standard":18},[],{"EN":85,"VI":85},{"EN":85,"VI":87},[90],[94,95,96],{"id":59,"indexDatabase":959,"url":74,"indexYears":18,"academicFieldIds":964,"indexDatabaseRanking":18},{"id":61,"createTime":62,"updateTime":63,"relativeEntities":960,"label":961,"description":962,"key":70,"publicationTags":963,"standard":18},[],{"EN":66,"VI":66},{"VI":68,"EN":69},[72,73],[76],{"volume":966,"pages":968},{"VOID":967},"152",{"VOID":969},"270-281","2020-07-01",2020,{"id":973,"createTime":974,"updateTime":975,"relativeEntities":976,"slug":977,"properties":978,"entityType":115,"verifyStatus":116,"verifyTime":985,"verifyNote":117,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":986,"fullTextUrl":18,"authors":987,"publicationType":253,"publisherRelationship":1003,"citationCount":18,"citationInfo":18,"publishDate":1031,"publishYear":1032,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":284},"0920e40c-10e7-4ac8-9d5e-4620cfa37384","2023-12-26T00:33:41.747+00:00","2025-01-17T23:54:38.753+00:00",[],"The-effect-of-powder-type-free-moisture-and-deformation-behaviour-of-granules-on-the-kinetics-of-fluid-bed-granulation",{"references":979,"title":981,"doi":983},{"VOID":980},"Talu, 2000, Computer simulation of wet granulation, Powder Technol., 110, 59, 10.1016\u002FS0032-5910(99)00268-5\nvon Smoluchowski, 1918, Versuch einer mathematischen Theorie der Koagulationskinetik kolloider Lösungen, Z. Phys. Chem., 92, 129, 10.1515\u002Fzpch-1918-9209\nWassam, 1992, Statistical mechanics, 713\nMüller, 1928, Zur allgemeinen Theorie der raschen Koagulation, Kolloidchem. Bech., 27, 223, 10.1007\u002FBF02558510\nM. Hounslow, Masters Course I, University of Sheffield, Sheffield, 2000 http:\u002F\u002Fwww.shef.ac.uk\u002Funi\u002Fprojects\u002Fppg\u002Fpbe.htm\nKapur, 1969, A coalescence model for granulation, Ind. Eng. Chem. Process Des. Dev., 8, 56, 10.1021\u002Fi260029a010\nKapur, 1981, Mathematical models of open-circuit balling or granulating devices, Ind. Eng. Chem. Process Des. Dev., 20, 519, 10.1021\u002Fi200014a022\nRamkrishna, 1985, The status of population balances, Rev. Chem. Eng., 3, 49, 10.1515\u002FREVCE.1985.3.1.49\nCryer, 1999, Modelling agglomeration processes in fluid-bed granulation, AIChE J., 45, 2069, 10.1002\u002Faic.690451005\nOuchiyama, 1975, The probability of coalescence in granulation kinetics, Ind. Eng. Chem. Process Des. Dev., 14, 286, 10.1021\u002Fi260055a016\nWatano, 1995, Kinetics of granule growth in fluidized bed granulation with moisture control, Chem. Pharm. Bull., 43, 1764, 10.1248\u002Fcpb.43.1764\nWatano, 1996, Mathematical model in the kinetics of agitation fluidized bed granulation. Effects of moisture content, damping speed and operation time on granule growth rate, Chem. Pharm. Bull., 44, 409, 10.1248\u002Fcpb.44.409\nOuchiyama, 1982, Kinetic analysis and simulation of batch granulation, Ind. Eng. Chem. Process Des. Dev., 21, 29, 10.1021\u002Fi200016a006\nTimoshenko, 1951, 372\nEnnis, 1991, A microlevel-based characterization of granulation phenomena, Powder Technol., 65, 257, 10.1016\u002F0032-5910(91)80189-P\nAdetayo, 2000, A new approach to modelling granulation processes for simulation and control purposes, Powder Technol., 108, 202, 10.1016\u002FS0032-5910(99)00221-1\nKristensen, 1985, Mechanical properties of moist agglomerates in relation to granulation mechanisms part II. Effects of particle size distribution, Powder Technol., 44, 239, 10.1016\u002F0032-5910(85)85005-1\nDrake, 1972, The scalar transport equation of coalescence theory: new families of exact solutions, J. Atmos. Sci., 29, 548, 10.1175\u002F1520-0469(1972)029\u003C0548:TSTEOC>2.0.CO;2\nPulvermacher, 1974, Similarity solutions of population balances, J. Colloid Interface Sci., 46, 428, 10.1016\u002F0021-9797(74)90052-6\nAdetayo, 1995, Population balance modelling of drum granulation of materials with wide size distribution, Powder Technol., 82, 37, 10.1016\u002F0032-5910(94)02896-V\nHounslow, 1988, A discretized population balance for nucleation, growth, and aggregation, AIChE J., 34, 1821, 10.1002\u002Faic.690341108\nLitster, 1995, Adjustable discretized population balance for growth and aggregation, AIChE J., 41, 591, 10.1002\u002Faic.690410317\nGelbard, 1980, Sectional representations for simulating aerosol dynamics, J. Colloid Interface Sci., 76, 541, 10.1016\u002F0021-9797(80)90394-X\nAbberger, 1994, Granule growth rates versus free humidity in fluid bed granulations, Eur. J. Pharm. Sci., 2, 110, 10.1016\u002F0928-0987(94)90147-3\nAbberger, 1999, Zur Kinetik der Wirbelschichtgranulierung, Pharmazie, 54, 611\nOrmos, 1973, Studies on granulation in a fluidized bed III. Calculation of the feed rate of granulating liquid, Hung. J. Ind. Chem., 1, 463\nAbberger, 1996, Instrumentation of a laboratory scale fluid-bed granulator for control of critical spray rate and of free moisture, Sci. Pharm., 64, 255\nT. Abberger, H. Egermann, Die freie Feuchte als Kriterium für den Kornbildungsmechanismus bei der Wirbelschichtgranulierung, 11th Scientific Congress of the Austrian Pharmaceutical Society, Graz, Austria, 1994.\n1994, 485\nSpencer, 1980, HP-67\u002F97 and TI-59 programs to fit the normal and log-normal distribution functions by linear regression, Powder Technol., 27, 219, 10.1016\u002F0032-5910(80)85026-1\n1987, 478\nR. Nimylowytsch, Diplomarbeit, University of Innsbruck, Innsbruck, 1995.\nOuchiyama, 1982, Kinetic analysis and simulation of batch granulation, Ind. Eng. Chem. Process Des. Dev., 21, 29, 10.1021\u002Fi200016a006\nLiu, 2000, Coalescence of deformable granules in wet granulation processes, AIChE J., 46, 529, 10.1002\u002Faic.690460312\nKristensen, 1996, Particle agglomeration in high shear mixers, Powder Technol., 88, 197, 10.1016\u002FS0032-5910(96)03123-3\nKristensen, 1984, Granulation in high speed mixers part 4. Effect of liquid saturation on the agglomeration, Pharm. Ind., 46, 763\nHolm, 1985, Granulation in high speed mixers part V. Power consumption and temperature changes during granulation, Powder Technol., 43, 213, 10.1016\u002F0032-5910(85)80002-4\nHuang, 1988, The granulation of partially prewetted alumina powders – a new concept in coalescence mechanism, Powder Technol., 55, 19, 10.1016\u002F0032-5910(88)80084-6\nKristensen, 1993, Granulations, 121\nSchaafsma, 1998, Description of agglomerate growth, Powder Technol., 97, 183, 10.1016\u002FS0032-5910(97)03399-8\nWaldie, 1991, Growth-mechanism and the dependence of granule size on drop size in fluidized-bed granulation, Chem. Eng. Sci., 46, 2781, 10.1016\u002F0009-2509(91)85147-P\nSchaefer, 1977, Control of fluidized bed granulation II. Estimation of droplet size of atomized binder solutions, Arch. Pharm. Chem. Sci. Ed., 5, 178",{"EN":982},"The effect of powder type, free moisture and deformation behaviour of granules on the kinetics of fluid-bed granulation",{"VOID":984},"10.1016\u002Fs0939-6411(01)00185-0","2025-01-17T23:54:38.752+00:00","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0939641101001850",[988],{"id":989,"sortIndex":19,"researcher":18,"roles":990,"affiliations":991,"properties":1000},"e7bb266b-5d25-46df-abc7-f12875d0944e",[124],[992],{"id":18,"sortIndex":19,"affiliation":993,"properties":18},{"id":994,"createTime":995,"updateTime":995,"relativeEntities":996,"slug":18,"properties":997,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"1a74061d-e23a-402f-9250-acc0ee691745","2023-12-18T09:10:52.765+00:00",[],{"title":998},{"VI":999},"Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innsbruck, Austria",{"title":1001},{"VI":1002},"Thomas Abberger",{"url":986,"publisher":1004,"properties":1026},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1005,"slug":10,"properties":1006,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1009,"manageAffiliations":1010,"indexDatabases":1011,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":1007,"title":1008},{"VOID":13},{"EN":15},[],[],[1012,1019],{"id":78,"indexDatabase":1013,"url":91,"indexYears":92,"academicFieldIds":1018,"indexDatabaseRanking":97},{"id":80,"createTime":81,"updateTime":82,"relativeEntities":1014,"label":1015,"description":1016,"key":88,"publicationTags":1017,"standard":18},[],{"EN":85,"VI":85},{"EN":85,"VI":87},[90],[94,95,96],{"id":59,"indexDatabase":1020,"url":74,"indexYears":18,"academicFieldIds":1025,"indexDatabaseRanking":18},{"id":61,"createTime":62,"updateTime":63,"relativeEntities":1021,"label":1022,"description":1023,"key":70,"publicationTags":1024,"standard":18},[],{"EN":66,"VI":66},{"VI":68,"EN":69},[72,73],[76],{"volume":1027,"pages":1029},{"VOID":1028},"52",{"VOID":1030},"327-336","2001-11-01",2001,{"id":1034,"createTime":1035,"updateTime":1036,"relativeEntities":1037,"slug":1038,"properties":1039,"entityType":115,"verifyStatus":116,"verifyTime":1036,"verifyNote":117,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":1044,"fullTextUrl":18,"authors":1045,"publicationType":253,"publisherRelationship":1088,"citationCount":18,"citationInfo":18,"publishDate":1115,"publishYear":1032,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":284},"cc89aecc-5371-4e67-93bf-3a258a789adc","2023-12-02T22:47:44.840+00:00","2025-01-01T23:54:21.657+00:00",[],"A-case-study-of-preservation-of-semi-solid-preparations-using-the-European-Pharmacopoeia-test-comparative-efficacy-of-antimicrobial-agents-in-zinc-gelatin",{"title":1040,"doi":1042},{"EN":1041},"A case study of preservation of semi-solid preparations using the European Pharmacopoeia test: comparative efficacy of antimicrobial agents in zinc gelatin",{"VOID":1043},"10.1016\u002Fs0939-6411(01)00164-3","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0939641101001643",[1046,1061,1076],{"id":1047,"sortIndex":242,"researcher":18,"roles":1048,"affiliations":1049,"properties":1058},"ab32fe02-a5b0-4e08-8cf7-ead7e3bd9d8f",[124],[1050],{"id":18,"sortIndex":19,"affiliation":1051,"properties":18},{"id":1052,"createTime":1053,"updateTime":1053,"relativeEntities":1054,"slug":18,"properties":1055,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"bdb293f8-9b99-40a8-a8e4-cec6922557f7","2023-12-02T22:47:44.894+00:00",[],{"title":1056},{"VI":1057},"Section de Biologie, University of Geneva, Geneva, Switzerland",{"title":1059},{"VI":1060},"Marie-Louise Chappuis",{"id":1062,"sortIndex":152,"researcher":18,"roles":1063,"affiliations":1064,"properties":1073},"2b36ab07-cace-4ca9-ab5d-0eb6c2388856",[124],[1065],{"id":18,"sortIndex":19,"affiliation":1066,"properties":18},{"id":1067,"createTime":1068,"updateTime":1068,"relativeEntities":1069,"slug":18,"properties":1070,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"e1418cdf-3cf4-4994-a2b8-04b4443a903e","2023-12-02T22:47:44.911+00:00",[],{"title":1071},{"VI":1072},"Section de Pharmacie, University of Geneva, Geneva, Switzerland",{"title":1074},{"VI":1075},"Eric Doelker",{"id":1077,"sortIndex":19,"researcher":18,"roles":1078,"affiliations":1079,"properties":1085},"46ef5fbd-1ab3-4625-92d4-3fabb357ea73",[124],[1080],{"id":18,"sortIndex":19,"affiliation":1081,"properties":18},{"id":1052,"createTime":1053,"updateTime":1053,"relativeEntities":1082,"slug":18,"properties":1083,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1084},{"VI":1057},{"title":1086},{"VI":1087},"Jocelyne Favet",{"url":1044,"publisher":1089,"properties":1111},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1090,"slug":10,"properties":1091,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1094,"manageAffiliations":1095,"indexDatabases":1096,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":1092,"title":1093},{"VOID":13},{"EN":15},[],[],[1097,1104],{"id":78,"indexDatabase":1098,"url":91,"indexYears":92,"academicFieldIds":1103,"indexDatabaseRanking":97},{"id":80,"createTime":81,"updateTime":82,"relativeEntities":1099,"label":1100,"description":1101,"key":88,"publicationTags":1102,"standard":18},[],{"EN":85,"VI":85},{"EN":85,"VI":87},[90],[94,95,96],{"id":59,"indexDatabase":1105,"url":74,"indexYears":18,"academicFieldIds":1110,"indexDatabaseRanking":18},{"id":61,"createTime":62,"updateTime":63,"relativeEntities":1106,"label":1107,"description":1108,"key":70,"publicationTags":1109,"standard":18},[],{"EN":66,"VI":66},{"VI":68,"EN":69},[72,73],[76],{"volume":1112,"pages":1113},{"VOID":1028},{"VOID":1114},"255-259","2001-09-01",{"id":1117,"createTime":1118,"updateTime":1119,"relativeEntities":1120,"slug":1121,"properties":1122,"entityType":115,"verifyStatus":116,"verifyTime":1119,"verifyNote":117,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":242,"primaryUrl":1127,"fullTextUrl":18,"authors":1128,"publicationType":253,"publisherRelationship":1185,"citationCount":18,"citationInfo":18,"publishDate":1213,"publishYear":1214,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":284},"d48b4b50-8829-4ff3-931e-5a5a4599b74c","2024-01-27T21:46:44.398+00:00","2024-12-31T23:54:10.373+00:00",[],"Synthesis-characterization-and-in-vitro-release-of-5-aminosalicylic-acid-and-5-acetyl-aminosalicylic-acid-of-polyanhydride-P-CBFAS-",{"title":1123,"doi":1125},{"EN":1124},"Synthesis, characterization and in vitro release of 5-aminosalicylic acid and 5-acetyl aminosalicylic acid of polyanhydride – P(CBFAS)",{"VOID":1126},"10.1016\u002Fs0939-6411(02)00191-1","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0939641102001911",[1129,1146,1158,1170],{"id":1130,"sortIndex":152,"researcher":18,"roles":1131,"affiliations":1132,"properties":1143},"533d6331-a429-429a-a245-ebfdf4c613c9",[124],[1133],{"id":18,"sortIndex":19,"affiliation":1134,"properties":18},{"id":1135,"createTime":1136,"updateTime":1137,"relativeEntities":1138,"slug":1139,"properties":1140,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"0496c651-8e24-4633-94ee-daaa8731cee9","2024-04-15T07:15:11.670+00:00","2025-06-11T17:50:27.020+00:00",[],"Department-of-Polymer-Science-and-Engineering-Zhejiang-University-Hangzhou-People-s-Republic-of-China",{"title":1141},{"EN":1142},"Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, People’s Republic of China",{"title":1144},{"VI":1145},"D Chen",{"id":1147,"sortIndex":19,"researcher":18,"roles":1148,"affiliations":1149,"properties":1155},"4cb93e5f-71cc-4093-a791-92ba30aefca8",[124],[1150],{"id":18,"sortIndex":19,"affiliation":1151,"properties":18},{"id":1135,"createTime":1136,"updateTime":1137,"relativeEntities":1152,"slug":1139,"properties":1153,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1154},{"EN":1142},{"title":1156},{"VI":1157},"Q.X Cai",{"id":1159,"sortIndex":242,"researcher":18,"roles":1160,"affiliations":1161,"properties":1167},"af4868e1-06ae-4567-92d7-aab1da4c2b75",[124],[1162],{"id":18,"sortIndex":19,"affiliation":1163,"properties":18},{"id":1135,"createTime":1136,"updateTime":1137,"relativeEntities":1164,"slug":1139,"properties":1165,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1166},{"EN":1142},{"title":1168},{"VI":1169},"K.J Zhu",{"id":1171,"sortIndex":165,"researcher":18,"roles":1172,"affiliations":1173,"properties":1182},"f5e3435d-5ff6-4e00-9554-8500eb62c3e6",[124],[1174],{"id":18,"sortIndex":19,"affiliation":1175,"properties":18},{"id":1176,"createTime":1177,"updateTime":1177,"relativeEntities":1178,"slug":18,"properties":1179,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"ba3d045d-dd8a-4553-9845-de402e1b64c8","2024-01-27T21:46:44.447+00:00",[],{"title":1180},{"VI":1181},"Department of Applied Chemistry, Zhejiang Institute of Science and Technology, Hangzhou, People's Republic of China",{"title":1183},{"VI":1184},"L.P Gao",{"url":1127,"publisher":1186,"properties":1208},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1187,"slug":10,"properties":1188,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1191,"manageAffiliations":1192,"indexDatabases":1193,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":1189,"title":1190},{"VOID":13},{"EN":15},[],[],[1194,1201],{"id":78,"indexDatabase":1195,"url":91,"indexYears":92,"academicFieldIds":1200,"indexDatabaseRanking":97},{"id":80,"createTime":81,"updateTime":82,"relativeEntities":1196,"label":1197,"description":1198,"key":88,"publicationTags":1199,"standard":18},[],{"EN":85,"VI":85},{"EN":85,"VI":87},[90],[94,95,96],{"id":59,"indexDatabase":1202,"url":74,"indexYears":18,"academicFieldIds":1207,"indexDatabaseRanking":18},{"id":61,"createTime":62,"updateTime":63,"relativeEntities":1203,"label":1204,"description":1205,"key":70,"publicationTags":1206,"standard":18},[],{"EN":66,"VI":66},{"VI":68,"EN":69},[72,73],[76],{"volume":1209,"pages":1211},{"VOID":1210},"55",{"VOID":1212},"203-208","2003-03-01",2003,{"id":1216,"createTime":1217,"updateTime":1218,"relativeEntities":1219,"slug":1220,"properties":1221,"entityType":115,"verifyStatus":116,"verifyTime":1228,"verifyNote":117,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":1229,"fullTextUrl":18,"authors":1230,"publicationType":253,"publisherRelationship":1294,"citationCount":18,"citationInfo":18,"publishDate":1322,"publishYear":1323,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":284},"b1cd300a-d714-4b76-a0e2-1eddc51eed77","2023-12-06T06:45:57.861+00:00","2025-01-23T23:52:27.843+00:00",[],"Edible-solid-foams-as-porous-substrates-for-inkjet-printable-pharmaceuticals",{"references":1222,"title":1224,"doi":1226},{"VOID":1223},"FDA, Paving the way for personalized medicine, 2013.\nE. Cone, A. Gregory, Healthcare Gets Personal, Oxford, 2016. http:\u002F\u002Fwww.oxfordeconomics.com\u002Fmy-oxford\u002Fprojects\u002F330885 (accessed 08.08.17).\nPritchard, 2017, Strategies for integrating personalized medicine into healthcare practice, Per. Med., 14, 141, 10.2217\u002Fpme-2016-0064\nSchork, 2015, Personalized medicine: time for one-person trials, Nature, 520, 609, 10.1038\u002F520609a\nLind, 2017, Social aspects in additive manufacturing of pharmaceutical products, Expert Opin, Drug Deliv. 14\nAlomari, 2015, Personalised dosing: Printing a dose of one’s own medicine, Int. J. Pharm., 494, 568, 10.1016\u002Fj.ijpharm.2014.12.006\nKolakovic, 2013, Printing technologies in fabrication of drug delivery systems, Expert Opin. Drug Deliv., 10, 1711, 10.1517\u002F17425247.2013.859134\nCheow, 2015, Combining inkjet printing and amorphous nanonization to prepare personalized dosage forms of poorly-soluble drugs, Eur. J. Pharm. Biopharm., 96, 314, 10.1016\u002Fj.ejpb.2015.08.012\nMontenegro-Nicolini, 2017, Inkjet printing of proteins: an experimental approach, AAPS J., 19, 234, 10.1208\u002Fs12248-016-9997-8\nGlaxoSmithKline plc, Liquid dispensing technology (LDT), 2015. http:\u002F\u002Fwww.gsk.com\u002Fmedia\u002F279688\u002Fliquid-dispensing-technology-leaflet.pdf (accessed 26.09.16).\nEdinger, 2017, Visualization and non-destructive quantification of inkjet-printed pharmaceuticals on different substrates using Raman spectroscopy and Raman chemical imaging, Pharm. Res., 34, 1023, 10.1007\u002Fs11095-017-2126-2\nGenina, 2013, Evaluation of different substrates for inkjet printing of rasagiline mesylate, Eur. J. Pharm. Biopharm., 85, 1075, 10.1016\u002Fj.ejpb.2013.03.017\nBuanz, 2011, Preparation of personalized-dose salbutamol sulphate oral films with thermal ink-jet printing, Pharm. Res., 28, 2386, 10.1007\u002Fs11095-011-0450-5\nD. Raijada, N. Genina, D. Fors, E. Wisaeus, J. Peltonen, J. Rantanen, N. Sandler, A step towards development of printable dosage forms for poorly soluble drugs, 102 (2013) 3694–3704. doi: 10.1002\u002Fjps.23678.\nHirshfield, 2014, Dropwise additive manufacturing of pharmaceutical products for solvent-based dosage forms, J. Pharm. Sci., 103, 496, 10.1002\u002Fjps.23803\nGenina, 2013, Behavior of printable formulations of loperamide and caffeine on different substrates - effect of print density in inkjet printing, Int. J. Pharm., 453, 488, 10.1016\u002Fj.ijpharm.2013.06.003\nDixit, 2009, Oral strip technology: overview and future potential, J. Control. Release, 139, 94, 10.1016\u002Fj.jconrel.2009.06.014\nPardeike, 2011, Nanosuspensions as advanced printing ink for accurate dosing of poorly soluble drugs in personalized medicines, Int. J. Pharm., 420, 93, 10.1016\u002Fj.ijpharm.2011.08.033\nElele, 2010, Electrodeless electrohydrodynamic printing of personalized medicines, Appl. Phys. Lett., 97, 10.1063\u002F1.3524512\nPalo, 2017, Development of oromucosal dosage forms by combining electrospinning and inkjet printing, Mol. Pharm., 14, 808, 10.1021\u002Facs.molpharmaceut.6b01054\nElele, 2012, Electrodeless elctrohydrodynamic drop-on-demand encapsulation of drugs into porous polymer films for fabrication of personalized dosage units, J. Pharm. Sci., 101, 2523, 10.1002\u002Fjps.23165\nSiimon, 2015, Mechanical characterization of electrospun gelatin scaffolds cross-linked by glucose, J. Mater. Sci. - Mater. Med., 26, 37, 10.1007\u002Fs10856-014-5375-1\nZhang, 2017, Electrospinning design of functional nanostructures for biosensor applications, J. Mater. Chem. B, 5, 1699, 10.1039\u002FC6TB03121H\nLiu, 2017, Electrospinnability of Poly Lactic-co-glycolic Acid (PLGA): the role of solvent type and solvent composition, Pharm. Res., 34, 738, 10.1007\u002Fs11095-017-2100-z\nL. Rey, J.C. May, D.Q. Wang, Freeze-drying\u002Flyophilization of pharmaceutical and biological products, in: L. Rey, J.C. May (Eds.), Free. Pharm. Biol. Prod., 3rd ed., Informa Healthcare, New York, London, 2010, pp. 1–564. http:\u002F\u002Fwww.gbv.de\u002Fdms\u002Fbs\u002Ftoc\u002F376091975.pdf (accessed 08.08.17).\nDehghan, 2012, Freeze-dried Xanthan\u002FGuar Gum Nasal Inserts for the Delivery of Metoclopramide Hydrochloride, Iran. J. Pharm. Res. IJPR., 11, 513\nKhorasani, 2015, Visualization and prediction of porosity in roller compacted ribbons with near-infrared chemical imaging (NIR-CI), J. Pharm. Biomed. Anal., 109, 11, 10.1016\u002Fj.jpba.2015.02.008\nGenina, 2012, Tailoring controlled-release oral dosage forms by combining inkjet and flexographic printing techniques, Eur. J. Pharm. Sci., 47, 615, 10.1016\u002Fj.ejps.2012.07.020\nModamio, 1996, Development and validation of liquid chromatography methods for the quantitation of propranolol, metoprolol, atenolol and bisoprolol: Application in solution stability studies, Int. J. Pharm., 130, 137, 10.1016\u002F0378-5173(95)04257-1\nBorges, 2015, Oral films: Current status and future perspectives, J. Control. Release, 206, 1, 10.1016\u002Fj.jconrel.2015.03.006\nA. Krekeler, Formulation development and manufacturing of oral film preparations, in: PBP Worldmeeting, Glasgow, the United Kingdom, 2016.\nBoateng, 2010, Characterisation of freeze-dried wafers and solvent evaporated films as potential drug delivery systems to mucosal surfaces, Int. J. Pharm., 389, 24, 10.1016\u002Fj.ijpharm.2010.01.008\nKassem, 2015, Lyophilized sustained release mucoadhesive chitosan sponges for buccal buspirone hydrochloride delivery: formulation and in vitro evaluation, AAPS PharmSciTech., 16, 537, 10.1208\u002Fs12249-014-0243-3\nNussinovitch, 1993, Compressive characteristics of freeze-dried agar and alginate gel sponges, Biotechnol. Prog., 9, 101, 10.1021\u002Fbp00019a015\nGarsuch, 2009, Novel analytical methods for the characterization of oral wafers, Eur. J. Pharm. Biopharm., 73, 195, 10.1016\u002Fj.ejpb.2009.05.010\nAyensu, 2012, In vitro characterisation of chitosan based xerogels for potential buccal delivery of proteins, Carbohydr. Polym., 89, 935, 10.1016\u002Fj.carbpol.2012.04.039\nBoateng, 2009, In vitro drug release studies of polymeric freeze-dried wafers and solvent-cast films using paracetamol as a model soluble drug, Int. J. Pharm., 378, 66, 10.1016\u002Fj.ijpharm.2009.05.038\nVrentas, 1996, Surface concentration effects in the drying of solvent-coated polymer films, J. Appl. Polym. Sci., 60, 1049, 10.1002\u002F(SICI)1097-4628(19960516)60:7\u003C1049::AID-APP16>3.0.CO;2-W\nAyensu, 2012, Development and physico-mechanical characterisation of lyophilised chitosan wafers as potential protein drug delivery systems via the buccal mucosa, Colloids Surfaces B Biointerfaces., 91, 258, 10.1016\u002Fj.colsurfb.2011.11.004\nKianfar, 2014, Development and physico-mechanical characterization of carrageenan and poloxamer-based lyophilized matrix as a potential buccal drug delivery system, Drug Dev. Ind. Pharm., 40, 361, 10.3109\u002F03639045.2012.762655\nT. Rogers, Hypromellose, in: C. Rowe, P. Sheskey, M. Quinn (Eds.), Handb. Pharm. Excipients, 6th ed., Pharmaceutical Press and American Pharmacists Association, London Chicago, 2009, pp. 326–329.\nJ. Collett, Poloxamer, in: C. Rowe, P. Sheskey, M.E. Quinn (Eds.), Handb. Pharm. Excipients, 6th ed., Pharmaceutical Press and American Pharmacists Association, 2009, pp. 506–509.\nLim, 2013, Plasticizer effects on physical-mechanical properties of solvent cast soluplus® films, AAPS PharmSciTech., 14, 903, 10.1208\u002Fs12249-013-9971-z\nBartolomei, 1998, Thermal studies on the polymorphic modifications of (R, S) propranolol hydrochloride, Thermochim. Acta. 321, 43, 10.1016\u002FS0040-6031(98)00438-9\nVakili, 2016, Application of a colorimetric technique in quality control for printed pediatric orodispersible drug delivery systems containing propranolol hydrochloride, Int. J. Pharm., 511, 606, 10.1016\u002Fj.ijpharm.2016.07.032\nShaikh, 2011, Mucoadhesive drug delivery systems, J. Pharm. Bioallied Sci., 3, 89, 10.4103\u002F0975-7406.76478",{"EN":1225},"Edible solid foams as porous substrates for inkjet-printable pharmaceuticals",{"VOID":1227},"10.1016\u002Fj.ejpb.2019.01.004","2025-01-23T23:52:27.842+00:00","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0939641118307951",[1231,1246,1258,1270,1282],{"id":1232,"sortIndex":122,"researcher":18,"roles":1233,"affiliations":1234,"properties":1243},"b966dde5-136a-428d-b37e-c9948249c685",[124],[1235],{"id":18,"sortIndex":19,"affiliation":1236,"properties":18},{"id":1237,"createTime":1238,"updateTime":1238,"relativeEntities":1239,"slug":18,"properties":1240,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"bafd476f-cbdc-48bc-aafb-b84b79f31663","2023-12-06T06:45:44.651+00:00",[],{"title":1241},{"VI":1242},"University of Copenhagen, Department of Pharmacy, Universitetsparken 2, DK-2100 Copenhagen, Denmark",{"title":1244},{"VI":1245},"Natalja Genina",{"id":1247,"sortIndex":165,"researcher":18,"roles":1248,"affiliations":1249,"properties":1255},"e2804569-5d99-4752-acdc-61f7443e28ec",[124],[1250],{"id":18,"sortIndex":19,"affiliation":1251,"properties":18},{"id":1237,"createTime":1238,"updateTime":1238,"relativeEntities":1252,"slug":18,"properties":1253,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1254},{"VI":1242},{"title":1256},{"VI":1257},"Jukka Rantanen",{"id":1259,"sortIndex":152,"researcher":18,"roles":1260,"affiliations":1261,"properties":1267},"3859dfd6-c087-4fcf-853a-8bc624169717",[124],[1262],{"id":18,"sortIndex":19,"affiliation":1263,"properties":18},{"id":1237,"createTime":1238,"updateTime":1238,"relativeEntities":1264,"slug":18,"properties":1265,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1266},{"VI":1242},{"title":1268},{"VI":1269},"Daniel Bar-Shalom",{"id":1271,"sortIndex":242,"researcher":18,"roles":1272,"affiliations":1273,"properties":1279},"b6fec0dc-aa26-49fc-bbb5-6f5b46eaf28e",[124],[1274],{"id":18,"sortIndex":19,"affiliation":1275,"properties":18},{"id":1237,"createTime":1238,"updateTime":1238,"relativeEntities":1276,"slug":18,"properties":1277,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1278},{"VI":1242},{"title":1280},{"VI":1281},"Magnus Edinger",{"id":1283,"sortIndex":19,"researcher":18,"roles":1284,"affiliations":1285,"properties":1291},"4fc9f7f9-3ab4-4dfd-b0ae-f7d694fdc8a9",[124],[1286],{"id":18,"sortIndex":19,"affiliation":1287,"properties":18},{"id":1237,"createTime":1238,"updateTime":1238,"relativeEntities":1288,"slug":18,"properties":1289,"entityType":54,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1290},{"VI":1242},{"title":1292},{"VI":1293},"Laura-Diana Iftimi",{"url":1229,"publisher":1295,"properties":1317},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1296,"slug":10,"properties":1297,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1300,"manageAffiliations":1301,"indexDatabases":1302,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":1298,"title":1299},{"VOID":13},{"EN":15},[],[],[1303,1310],{"id":78,"indexDatabase":1304,"url":91,"indexYears":92,"academicFieldIds":1309,"indexDatabaseRanking":97},{"id":80,"createTime":81,"updateTime":82,"relativeEntities":1305,"label":1306,"description":1307,"key":88,"publicationTags":1308,"standard":18},[],{"EN":85,"VI":85},{"EN":85,"VI":87},[90],[94,95,96],{"id":59,"indexDatabase":1311,"url":74,"indexYears":18,"academicFieldIds":1316,"indexDatabaseRanking":18},{"id":61,"createTime":62,"updateTime":63,"relativeEntities":1312,"label":1313,"description":1314,"key":70,"publicationTags":1315,"standard":18},[],{"EN":66,"VI":66},{"VI":68,"EN":69},[72,73],[76],{"volume":1318,"pages":1320},{"VOID":1319},"136",{"VOID":1321},"38-47","2019-03-01",2019]